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Achalasia is a rare condition with an annual incidence of 1 per 100.000 in the western world, 
an equal prevalence in men and women and a peak incidence around 60 years of age. Acha-
lasia is a motility disorder in which failed relaxation of the lower esophageal sphincter in 
combination with diminished peristalsis of the distal esophagus causes a functional obstruc-
tion of the esophagus 1. The characteristic symptoms are dysphagia for solids and liquids, 
regurgitation of undigested food or saliva, respiratory complaints (nocturnal cough, aspira-
tion), retrosternal pain and weight loss. The diagnosis is made by esophageal manometry 
and a timed barium esophagram. Upper gastrointestinal endoscopy is performed to exclude 
mechanical obstruction such as due to an esophageal malignancy. 
Since 1975 all patients referred to our centre with the suspicion of achalasia were analyzed, 
treated and followed according to a fixed protocol. More than 400 patients were included in 
the cohort up till now. They were diagnosed and treated by a limited number of physicians. 
The size and follow up of this cohort is unique and offers opportunities for research.
The etiology of achalasia is still unclear, although there are some studies suggesting 
an underlying autoimmune process 2, 3. In resection specimen of patients with achalasia, 
inflammation was observed around the myenteric plexus 4. Nitric oxide is implicated in the 
inhibitory response of the lower esophageal sphincter, however neurons containing nitric 
oxide are absent in the myenteric plexus of achalasia patients 5. The inflammatory infiltrate 
within the myenteric plexus predominantly contains CD3-positive T-lymfocytes 4, 6, which 
has led to the hypothesis that an autoimmune process may underlie achalasia, leading to 
an inflammatory process and neuronal cell loss. HSV-1 viral antigen has been proposed as 
evoking agent but due to conflicting evidence the exact etiology remains undissolved 7-9. 
In case of an auto-immune etiology, it is likely that other auto-immune diseases are more 
common in patients with achalasia. We therefore studied the prevalence of auto-immune 
thyroid disease in our cohort of achalasia patients and compared this to the prevalence in the 
general population (chapter 8). 
 Since the etiology of achalasia is still unclear, treatment is purely symptomatic aiming 
at improvement of food passage by lowering of the LES-pressure. There are several treat-
ment options of which pneumatic dilatation and laparoscopic myotomy are the two most 
commonly applied 10. Pneumatic dilatation is an effective treatment with low complication 
risk, which can be performed as an out patient procedure 11-13. A recent randomized study 
with two years follow-up showed that laparoscopic myotomy and pneumatic dilatation were 
equally effective 14. In chapter 7 we report the long term success of pneumatic dilatation 
using our stepwise pneumatic dilatation protocol with incremental diameter balloons to 40 
mm on 3 consecutive days. The aim of this study was to define predictors of success and 
failure to facilitate treatment choices. 
Adequate treatment with sufficient symptom control does not prevent that patients suffer 
from persistent esophageal distension with retention of foods and fluids, bacterial over-
growth and impaired clearance of regurgitated acid gastric contents. These factors can lead 
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to chronic inflammation of the esophageal mucosa, which potentially increases the risk of 
development of hyperplasia, dysplasia and esophageal cancer 15, 16. On the other hand lower-
ing of LES-pressure can aggravate acid gastro esophageal reflux leading to reflux esophagitis, 
Barrett’s metaplasia 17 and adenocarcinoma 18-20. 
This suggests that inflammation is likely to be a common condition in achalasia. In chapter 
3 the incidence and severity of histological and endoscopical inflammation during follow up 
of achalasia patients was studied. We also investigated the association between inflamma-
tion and food stasis. 
Although it is generally accepted that achalasia is a risk factor for esophageal cancer de-
velopment, the reported relative risks varies between nil and 140 21-30. These large variations 
are due to differences in study design, cohort size and length of follow-up. In Chapter 4 we 
report the incidence of esophageal carcinoma in our cohort and evaluate the efficacy of long 
term endoscopical surveillance.
As mentioned, adequate treatment of achalasia induces gastro-esophageal reflux, which 
can lead to Barrett’s metaplasia and esophageal adenocarcinoma. Only few data exist on 
the development of Barrett’s esophagus in patients with achalasia treated with pneumatic 
dilatation. In Chapter 5 the incidence of, and risk factors for Barrett’s esophagus and the 
development of adenocarcinoma in achalasia patients after dilatation treatment in our large 
cohort are determined. 
Without surveillance, achalasia patients with esophageal carcinoma usually present in an 
advanced stage with poor prognosis. This is enhanced by the fact that achalasia patients are 
used to delayed esophageal emptying and only report worsening of these symptoms due to 
development of an obstructive tumor at a late stage 31. Little data exist concerning the benefit 
of surveillance, but so far, this does not seem cost effective nor to improve prognosis 26, 28, 31, 32.
Optimization of surveillance is necessary to detect neoplastic progression at an early and 
curable stage. Surveillance is often difficult to perform due to several reasons. Food stasis and 
mucosal adherence of food makes a careful inspection difficult. Furthermore most carcino-
mas develop in het middle and distal third of the esophagus and therefore the whole length 
of the esophagus should be carefully inspected and sampled. At last, histological evaluation 
of dysplasia can be difficult due to the persistent presence of chronic inflammation. Probably 
the surveillance may be improved by the use of specific histological markers or lugol staining. 
In chapter 6 we investigated whether the expression of the tumor suppressor gene p53 and 
proliferation marker Ki67 on surveillance biopsy samples are early predictors for malignant 
transformation. 
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ABSTRACT
Achalasia is a motility disorder of the esophagus of unknown origin, in which loss of relax-
ation of the lower esophageal sphincter and aperistalsis in the distal esophagus leads to a 
functional esophageal obstruction. The treatment is symptomatic, aiming at lowering of the 
LES-pressure and may be accompanied by various side effects, including gastro-esophageal 
reflux, a risk factor for esophagitis and its complications. Stasis and fermentation can also 
lead to inflammation of the esophageal mucosa, giving rise to hyperplasia of the epithelium, 
multifocal dysplasia and in some patients eventually squamous cell carcinoma. Unfortu-
nately, the sensitivity and specificity of endoscopical inspection to assess inflammation or 
dysplasia of the esophageal lining is low, such that biopsy sampling is necessary for accurate 
assessment. 
Although it is generally accepted that achalasia is a pre-malignant disorder, the reported 
increased risk of patients with achalasia to develop a squamous cell carcinoma varies from 
0 – 140 times that of the normal population. In addition achalasia may predispose to Barrett’s 
metaplasia and esophageal adenocarcinoma, which have been described in case reports 
after myotomy. 
Surveillance-endoscopies with tissue sampling to detect pre-neoplastic lesions has been 
recommended, even though this can be very difficult due to mucosal adherence of food as 
well as hyperplastic changes of the mucosa. In the event of moderate to severe inflammation 
and/or persisting stasis of food despite adequate LES-pressure lowering therapy, the surveil-
lance interval should be shortened and performed after a three-day liquid diet. The exact 
technique and time-intervals still need to be established, however.      
KEy wORdS
Achalasia, Barrett’s esophagus, carcinoma, esophagitis, reflux, surveillance, 
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InTROduCTIOn
Achalasia is a rare condition with an annual incidence of 1 per 100,000, in which failed re-
laxation of the lower esophageal sphincter (LES) in combination with diminished peristalsis 
of the distal esophagus causes a functional obstruction of the esophagus 1. The etiology of 
this disorder is still unclear, although there are some studies suggesting an underlying auto-
immune process 2, 3. The diagnosis is made by esophageal manometry and a timed barium 
esophagram. Upper gastrointestinal endoscopy is performed to exclude mechanical obstruc-
tion. Since the etiology is still unclear, treatment is purely symptomatic aiming at improving 
the passage of food by lowering of the LES-pressure. There are several treatment options of 
which pneumatic dilatation and laparoscopic myotomy are the two most commonly applied 
4. 
Despite therapy, food -stasis often persists, which may contribute to the development of 
chronic inflammation, dysplasia and eventually squamous cell carcinoma. For this reason 
achalasia is considered to be a pre-malignant disorder, however the reported risks for de-
velopment of squamous cell cancer of the esophagus vary widely and the benefit of surveil-
lance is often the subject of debate. Apart from esophageal food stasis and fermentation, 
esophagitis may in theory also directly result from the LES-lowering therapy, which may 
enhance gastro-esophageal reflux, another risk factor for esophagitis and its complications, 
in particular Barrett’s metaplasia and adenocarcinoma. 
This review focuses on esophagitis, metaplasia and dysplasia in achalasia patients, and 
their importance for the management and follow-up of these patients.
ESOPhAGITIS
The treatment of achalasia aims at reduction of the LES pressure to relieve dysphagia. This is 
usually achieved by pneumatic dilatation or myotomy, techniques which may induce signifi-
cant sphincter insufficiency. This may in theory lead to significant gastro-esophageal reflux, 
potentially leading to microscopic and macroscopic signs of esophagitis. On the other hand 
insufficient treatment of the non-relaxing sphincter is associated with chronic stasis and 
intraluminal fermentation of food, which may also predispose to esophagitis. This intricate 
balance suggests that esophagitis is likely to be a common condition in achalasia patients, 
yet data regarding this issue are very scarce.
Reflux after surgical myotomy may occur in up to 60 % of patients, and for many surgeons 
this is a reason to combine myotomy with a fundoplication. Reflux after pneumatic dilatation 
has not been widely studied, and is reported to be less than 10 % in the few available reports 
5-8. 
About half of the newly diagnosed achalasia patients complain about pyrosis prior to any 
therapy aiming at reducing LES pressure 9. Abnormal acid exposure before LES-lowering 
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therapy has been reported by Shoenut et al in 10 of 48 (21%) achalasia patients and by Smart 
et al in 1 of 17 patients 10, 11. This abnormal acid exposure could be due to gastro-oesophageal 
reflux, but can also be caused by ingestion of acidic food or lactic acid production after bacte-
rial fermentation of retained food 11. Differentiation between these two mechanisms can be 
easily made by 24-hour intra-esophageal pH-monitoring. Patients with gastro-esophageal 
reflux show sharp pH drops, whereas a steady drift of the pH to below pH 4 is typical for 
fermentation 12,  13. It is most likely that the reported abnormal acid exposure in achalasia 
patients is caused by the latter in particular 11,  12.   
We previously evaluated the incidence of esophagitis in 1102 biopsy samples of 251 pa-
tients with achalasia, treated with pneumatic dilatation. Forty percent of patients developed 
moderate to severe esophagitis (Ismail-Beigi grade 2 or 3) after a mean follow-up of 8.4 years 
14. We showed that this inflammation was indeed caused by food stasis and that the sensibil-
ity of endoscopy to assess inflammation was quite low 15. 
Our results show that inflammation is a common finding in patients with achalasia treated 
with pneumatic dilatation. The assumption that inflammation predisposes to hyperplasia 
and dysplasia underlines the necessity to obtain esophageal biopsy samples during follow-
up of achalasia patients to score for esophagitis 16. Histological signs of moderate to severe 
esophagitis in combination with food stasis, or moderate to marked food stasis alone, form an 
indication for retreatment if possible. Nowadays, most clinicians wait for the patient to report 
symptom worsening before offering repeated LES dilatation. However, it is well known that 
achalasia patients tend to underreport their symptoms for several reasons. This includes the 
fact that they are used to symptoms of poor esophageal clearance, which often has already 
existed for a very long time even before the first treatment is given. Other reasons for under-
reporting symptoms are the discomfort of treatment and, in particular in elderly achalasia 
patients, an altered vagal afferent response leading to a diminished perception of pain 17, 18.
BARRETT’S METAPLASIA And AdEnOCARCInOMA
Barrett’s metaplasia and achalasia appear as contradictions, but the co-existence of these 
disorders has been reported in approximately 30 cases in the literature, most of them after 
myotomy and a few after dilatation 19, 20. Adenocarcinoma in Barrett’s metaplasia in achalasia 
has also been described 21, 22. In addition, there are some case reports of achalasia patients 
with Barrett’s metaplasia at the time of presentation even before LES-lowering therapy 20, 23. 
The pathogenesis of Barrett’s metaplasia in these patients is uncertain, but there are several 
potential mechanisms. First, intestinal metaplasia could be a complication of LES-lowering 
therapy inducing sphincter insufficiency and pathological reflux. Secondly, refluxed acid 
cannot be cleared from the a-peristaltic esophagus. Thirdly it could be the result of persistent 
acidic conditions due to fermentation of retained food. Finally, it is possible that the Barrett’s 
metaplasia existed prior to the development of achalasia 24.
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In our series of 331 achalasia patients treated with pneumatic dilatation 28 (8.5%) developed 
endoscopical evidence of Barrett’s metaplasia with intestinal metaplasia in the histological 
samples. Patients with a hiatal herniation were more likely to develop Barrett’s metaplasia 
(28% versus 3%). Also, a lower LES-pressure after dilatation predisposed to Barrett’s metapla-
sia (13.9 versus 17.4 mmHg) 25. This implies that pathological acid gastro- esophageal reflux 
is probably the main cause of development of Barrett’s metaplasia. One patient developed 
high-grade dysplasia and in 3 patients an adenocarcinoma was detected during follow-up. 
In the total group of 331 patients with achalasia the long-term incidence of adenocarcinoma 
was 1% 25.  
ESOPhAGEAL CARCInOMA
Achalasia is considered to be a pre-malignant disorder, although the reported risk of devel-
oping carcinoma varies enormously. Several autopsy studies have reported an esophageal 
neoplasia prevalence of 20 –29% in achalasia patients 26-28. The largest cohort follow-up study 
was conducted by Wychulis in 1318 patients with achalasia followed for 17 patient-years. This 
study revealed a seven-fold increased risk for esophageal cancer compared to the general 
population 29. Other follow-up studies report oesophageal cancer incidences varying from nil 
per 953 patient-years to 1 per 173 patient-years 30-32. This translates into relative risks varying from 
zero to 140 times increased compared to the sex- and age-adjusted population. An analysis 
of our group in 1995 on 195 patients followed for 4.5 years showed an esophageal cancer 
incidence of 1 per 293 patient-years 31. A direct comparison of all the conducted studies is 
difficult, because they differ in design and in their definitions of the actual start of follow-up, 
varying from the start of symptoms versus start of treatment. 
Patients with achalasia who develop esophageal cancer often have a dismal prognosis. This 
is at least in part due to the fact that these patients are used to symptoms of impaired food 
passage and often report worsening too late 33. This knowledge and the observation that the 
annual risk for cancer is comparable to the annual risk of developing neoplastic lesions in 
other inflammatory diseases of the gastro-intestinal mucosa, like Barrett’s metaplasia, war-
rant the consideration for surveillance. The benefit of surveillance strategies in achalasia is 
often argued. Surveillance should aim at both detection of neoplastic transformation at a 
curable stage and identification of patients mostly at risk of developing such a lesion, e.g 
patients with persistent severe inflammation or food stasis despite LES-lowering therapies 
and those with Barrett’s metaplasia. Surveillance in achalasia, however, is rather difficult to 
accomplish due to several reasons. First, stasis and mucosal adherence of food compromise a 
careful inspection. In case of severe stasis, endoscopy should be done after a three-day liquid 
diet, even more so because severe food stasis is probably a risk factor for cancer develop-
ment. Secondly most carcinomas develop in the middle and distal third of the esophagus 
and therefore, in contrast to Barrett’s esophagus, the whole length of the esophagus should 
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be sampled 34. Thirdly the surveillance-interval and the start time of follow-up need to be 
established, because the risk of cancer is related to duration of symptoms. 
In our opinion, surveillance endoscopy with tissue sampling should be performed in 
patients with longstanding achalasia, probably every three years. This surveillance should 
start no later than 15 years after onset of symptoms. In case of moderate to severe inflam-
mation and/or stasis of food persisting despite adequate LES-pressure lowering therapy, the 
surveillance interval should be shortened and the endoscopy should be performed after a 
three-day liquid diet. Lugol-staining may be of use in spotting suspicious areas and allow 
better sampling35.  
However, the exact technique and the time-intervals for surveillance need to be deter-
mined. 
COnCLuSIOnS
After pneumatic dilatation, a considerable proportion of patients with achalasia develop 
moderate to severe esophagitis. This inflammation is caused by stasis of food and can lead to 
dysplasia and development of squamous cell carcinoma. 
Barrett’s metaplasia and adenocarcinoma can also develop in treated achalasia patients. 
The cause is still unclear, but pathological acid gastro-esophageal reflux is probably an 
important factor. 
The risk of development of squamous cell carcinoma is substantially increased in achalasia 
patients compared to the healthy population. 
Surveillance is likely to be useful in detecting neoplastic lesions at a curable stage and in 
identifying the patients most at risk of developing such a lesion, e.g. those with persistent 
food stasis or moderate to severe inflammation. The optimal surveillance-technique and tim-
ing still need further study and improvement.
Ivonne Leeuwenburgh BW 3.indd   22 24-02-12   11:47
23
Long term risk of esophagitis, Barrett’s esophagus and esophageal cancer 
Ch
ap
te
r 2
REfEREnCES
 1. Richter JE. Oesophageal motility disorders. Lancet 2001;358:823-8.
 2. Verne GN, Sallustio JE, Eaker EY. Anti-myenteric neuronal antibodies in patients with achalasia. A 
prospective study. Dig Dis Sci 1997;42:307-13.
 3. Ruiz-de-Leon A, Mendoza J, Sevilla-Mantilla C, et al. Myenteric antiplexus antibodies and class II 
HLA in achalasia. Dig Dis Sci 2002;47:15-9.
 4. Spiess AE, Kahrilas PJ. Treating achalasia: from whalebone to laparoscope. Jama 1998;280:638-42.
 5. Csendes A, Braghetto I, Henriquez A, Cortes C. Late results of a prospective randomised 
study comparing forceful dilatation and oesophagomyotomy in patients with achalasia. Gut 
1989;30:299-304.
 6. Thomson D, Shoenut JP, Trenholm BG, Teskey JM. Reflux patterns following limited myotomy 
without fundoplication for achalasia. Ann Thorac Surg 1987;43:550-3.
 7. Yon J, Christensen J. An uncontrolled comparison of treatments for achalasia. Ann Surg 
1975;182:672-6.
 8. Andreollo NA, Earlam RJ. Heller’s myotomy for achalasia: is an added anti-reflux procedure neces-
sary? Br J Surg 1987;74:765-9.
 9. Spechler SJ, Souza RF, Rosenberg SJ, Ruben RA, Goyal RK. Heartburn in patients with achalasia. 
Gut 1995;37:305-8.
 10. Shoenut JP, Micflikier AB, Yaffe CS, Den Boer B, Teskey JM. Reflux in untreated achalasia patients. J 
Clin Gastroenterol 1995;20:6-11.
 11. Smart HL, Foster PN, Evans DF, Slevin B, Atkinson M. Twenty four hour oesophageal acidity in 
achalasia before and after pneumatic dilatation. Gut 1987;28:883-7.
 12. Burke CA, Achkar E, Falk GW. Effect of pneumatic dilation on gastroesophageal reflux in achalasia. 
Dig Dis Sci 1997;42:998-1002.
 13. Crookes PF, Corkill S, DeMeester TR. Gastroesophageal reflux in achalasia. When is reflux really 
reflux? Dig Dis Sci 1997;42:1354-61.
 14. Leeuwenburgh I, van Dekken H, Scholten P, Haringsma J, Siersema PD, Kuipers EJ. Esophagitis is 
very common in patients with achalasia after treatment with pneumatic dilatation. Gastroenter-
ology 2004;126:A-450.
 15. Leeuwenburgh I, van Dekken H, Scholten P, et al. Esophagitis in patients with achalasia after treat-
ment with pneumatic dilatation is caused by stasis of food. Gastroenterology 2005;128:A-636.
 16. Lehman MB, Clark SB, Ormsby AH, Rice TW, Richter JE, Goldblum JR. Squamous mucosal al-
terations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol 
2001;25:1413-8.
 17. Gonzalez M, Mearin F, Vasconez C, Armengol JR, Malagelada JR. Oesophageal tone in patients 
with achalasia. Gut 1997;41:291-6.
 18. Vaezi MF, Baker ME, Richter JE. Assessment of esophageal emptying post-pneumatic dilation: use 
of the timed barium esophagram. Am J Gastroenterol 1999;94:1802-7.
 19. Agha FP, Keren DF. Barrett’s esophagus complicating achalasia after esophagomyotomy. A clini-
cal, radiologic, and pathologic study of 70 patients with achalasia and related motor disorders. J 
Clin Gastroenterol 1987;9:232-7.
 20. Sprung DJ, Gibb SP. Barrett’s esophagus in a patient with achalasia. Am J Gastroenterol 
1985;80:330-3.
 21. Ellis FH, Jr., Gibb SP, Balogh K, Schwaber JR. Esophageal achalasia and adenocarcinoma in Barrett’s 
esophagus: a report of two cases and a review of the literature. Dis Esophagus 1997;10:55-60.
Ivonne Leeuwenburgh BW 3.indd   23 24-02-12   11:47
Chapter 2
24
 22. Goodman P, Scott LD, Verani RR, Berggreen CC. Esophageal adenocarcinoma in a patient with 
surgically treated achalasia. Dig Dis Sci 1990;35:1549-52.
 23. Guo JP, Gilman PB, Thomas RM, Fisher RS, Parkman HP. Barrett’s esophagus and achalasia. J Clin 
Gastroenterol 2002;34:439-43.
 24. Traube M. The acid achalasia association. J Clin Gastroenterol 2002;34:382-4.
 25. Scholten P, Leeuwenburgh I, Vaessen R, et al. Barrett’s esophagus after Pneumo-dilatation for 
achalasia. Gastroenterology 2004;126:A-635.
 26. Carter R, Brewer LA, III. Achalasia and esophageal carcinoma. Studies in early diagnosis for im-
proved surgical management. Am J Surg 1975;130:114-20.
 27. Lortat-Jacob JL, Richard CA, Fekete F, Testart J. Cardiospasm and esophageal carcinoma: report of 
24 cases. Surgery 1969;66:969-75.
 28. Just-Viera JO, Morris JD, Haight C. Achalasia and esophageal carcinoma. Ann Thorac Surg 
1967;3:526-38.
 29. Wychulis AR, Woolam GL, Andersen HA, Ellis FH, Jr. Achalasia and carcinoma of the esophagus. 
Jama 1971;215:1638-41.
 30. Chuong JJ, DuBovik S, McCallum RW. Achalasia as a risk factor for esophageal carcinoma. A reap-
praisal. Dig Dis Sci 1984;29:1105-8.
 31. Meijssen MA, Tilanus HW, van Blankenstein M, Hop WC, Ong GL. Achalasia complicated by oe-
sophageal squamous cell carcinoma: a prospective study in 195 patients. Gut 1992;33:155-8.
 32. Brucher BL, Stein HJ, Bartels H, Feussner H, Siewert JR. Achalasia and esophageal cancer: inci-
dence, prevalence, and prognosis. World J Surg 2001;25:745-9.
 33. Ribeiro U, Jr., Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma 
of the oesophagus. Br J Surg 1996;83:1174-85.
 34. Streitz JM, Jr., Ellis FH, Jr., Gibb SP, Heatley GM. Achalasia and squamous cell carcinoma of the 
esophagus: analysis of 241 patients. Ann Thorac Surg 1995;59:1604-9.
 35. Yamamuro EM, Cecconello I, Iriya K, Tomishigue T, Oliveira MA, Pinotti HW. Lugol dye endoscopy 
for analysis of esophageal mucosa in achalasia. Hepatogastroenterology 1999;46:1687-91.
Ivonne Leeuwenburgh BW 3.indd   24 24-02-12   11:47
Ivonne Leeuwenburgh BW 3.indd   25 24-02-12   11:47
Ivonne Leeuwenburgh BW 3.indd   26 24-02-12   11:47
Chapter 3 Inflammation
Esophagitis is common in patients with 
achalasia after pneumatic dilatation
Ivonne Leeuwenburgh1
Herman van Dekken2
Pieter Scholten1, 
Bettina E. Hansen1
Jelle Haringsma1
Peter D. Siersema1
Ernst J. Kuipers1
Departments of Gastro-enterology and Hepatology1, and Pathology2
Erasmus University Medical Centre Rotterdam, The Netherlands 
 
Aliment Pharmacol Ther. 2006;23:1197-203.
Ivonne Leeuwenburgh BW 3.indd   27 24-02-12   11:47
Chapter 3
28
ABSTRACT
Background: Achalasia, an esophageal motor disease, is associated with functional esopha-
geal obstruction. Food stasis can predispose for esophagitis. Treatment aims at lowering of 
the lower esophageal sphincter pressure, enhancing the risk of gastro-esophageal reflux. 
Nevertheless, the incidence of esophagitis after achalasia treatment is unknown. 
Methods: A cohort of 331 patients with achalasia were treated with pneumatic dilatation 
and followed. Esophagitis and stasis were assessed by endoscopy and inflammation was 
graded by histology. 
Results: 251 patients were followed for a mean 8.4 yrs (range 1-26). The average number 
of endoscopies with biopsy sample sets per patient was 4 (range 1-17). Three patients had 
no histological signs of esophagitis throughout follow-up, 139 had esophagitis grade 1, 
49 esophagitis grade 2, and 60 grade 3. Specialized intestinal metaplasia was found in 37 
patients. The association between endoscopic food stasis and histological inflammation was 
significant. The association between endoscopic signs of esophagitis and histological inflam-
mation was poor. 
Conclusions: Forty percent of the achalasia patients develop chronic active or ulcerating 
esophagitis after treatment. Inflammation was associated with food stasis. Since the sensitiv-
ity of endoscopy to detect inflammation is low, surveillance endoscopy with biopsy sampling 
and assessment of stasis is warranted to detect early neoplastic changes.   
KEywORdS:
Achalasia, esophagitis, inflammation, pneumatic dilatation, surveillance
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InTROduCTIOn
Achalasia is an uncommon disorder with a largely unknown aetiology, in which there is a 
loss of relaxation of the lower esophageal sphincter and a-peristalsis of the distal part of 
the esophagus 1. Treatment options are merely symptomatic and aim at lowering the 
LES -pressure to improve the passage of fluid and food. Pneumatic dilatation and laparoscopic 
myotomy are the two most commonly applied treatment modalities. Pneumatic dilatation is 
an effective treatment with low complication risk and can be performed as an outpatient 
procedure 2-4. 
Lowering LES-pressure not only intends to improve food passage but may also increase 
gastro-esophageal reflux. Such reflux is thought to be quite common after surgical myotomy, 
for this reason myotomy is often combined with an anti-reflux procedure 5. A previous study 
has reported that symptomatic reflux also may occur in patients after pneumatic dilatation 6. 
Complications of gastro-esophageal reflux, such as Barrett’s metaplasia and adenocarcinoma 
of the esophagus in patients treated for achalasia are incidentally reported 7-9.
Patients with achalasia also have an increased risk of developing squamous-cell carci-
noma of the esophagus. This is probably due to chronic inflammation and hyperplasia of the 
epithelium in response to stasis of food and fluid 10. In esophageal resection-specimens from 
patients with achalasia and esophageal squamous-cell carcinoma, a marked hyperplasia was 
found together with multiple dysplastic foci, which findings supports this hypothesis 11.
Even though achalasia patients thus have various significant risk factors for the develop-
ment of chronic esophagitis, a condition with long-term implications, little is known about 
the prevalence of this disorder in achalasia patients during follow-up. We therefore studied 
the incidence and severity of esophagitis in patients treated with pneumatic dilatation.  
MATERIAL And METhOdS
Patients
Between 1975 and 2003 all patients with achalasia referred to the Erasmus MC Rotterdam 
were diagnosed, treated and followed according to a strict protocol which did not change 
over time and which was carried out by a limited number of physicians. Achalasia was diag-
nosed by esophageal manometry. Aperistalsis of the distal part of the esophagus and loss 
of relaxation of the lower esophageal sphincter were considered diagnostic for achalasia. 
This diagnosis was supported by a timed barium esophagram in which stasis of contrast, 
a bird beak appearance and widening and elongation of the esophagus were considered 
compatible with achalasia. An upper gastro-intestinal (GI) endoscopy was performed to rule 
out secondary achalasia resulting from a neoplastic lesion. The treatment protocol consisted 
of three dilatation sessions on three consecutive days using Rigiflex balloon dilator (Boston 
Microvasive) with an increasing diameter of 30, 35 and 40 mm. The balloon was positioned in 
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the LES under fluoroscopic control and easily insufflated to a pressure of 300 mm Hg and kept 
insufflated for 1 minute. During insufflation there was attention for a waist and its possible 
disappearance. Treatment success was defined as relieve of symptoms (in particular regur-
gitation, vomiting and weight loss) regardless of improvement of the esophagram. Disease 
recurrence, was defined as deterioration of symptoms, and was primarily treated with pneu-
matic dilatation, whereas a myotomy was performed in patients who had responded poorly 
to previous dilatation. Patients were seen after 1, 2, 4 and 7 years of follow-up. This included 
recording of the medical history, use of medication and body weight. In addition esophageal 
manometry, upper G-I endoscopy and a timed barium esophagram was performed. Seven 
years after initial treatment, follow-up was continued three-yearly by upper G-I endoscopy 
with biopsy sampling.
Upper G-I endoscopy and biopsy sampling 
At each upper G-I endoscopy, the esophagus and gastro-esophageal junction were in-
spected for the presence of macroscopic esophagitis and, in a proportion of the endoscopies 
posterior, graded according the Los Angeles classification (grade A-D)12, Barrett’s metaplasia, 
carcinoma, and stasis of food (mild in case of retention of fluid only, moderate in case of 
some fluid and solids and severe when there is massive retention in which it was impossible 
to inspect the mucosa). Three to four biopsy specimens were sampled with standard forceps 
just above the gastro-esophageal junction. If there was suspicion of columnar metaplasia, 
dysplasia or carcinoma, additional biopsies were obtained.  In case of severe stasis, extensive 
irrigation and suction were applied to clean the esophagus. When this remained unsuccessful 
and proper examination of the mucosa remained impossible, the endoscopy was repeated 
after three days of liquid diet.
Histology
About 4 μm hematoxylin-eosin stained routine histological sections were used. An experi-
enced G-I pathologist blinded to the clinical data re-evaluated all samples. Esophagitis was 
assessed according to established criteria13-15. Using these criteria, the following lesions were 
considered compatible with reflux disease of increasing severity: (1) basal layer hyperplasia 
(2) elongation of papillae, (3) dilation of papillary vascular spaces, (4) intraepithelial inflam-
matory infiltration, (5) mucosal erosion and (6) granulation tissue. For practical purposes in-
flammation was graded into chronic (i.e. esophagitis grade 1, in the presence of criteria 1-3), 
chronic active (i.e. esophagitis grade 2, in the presence of criteria 4 with or without criteria 
1-3), or eroding ulcerating (i.e. esophagitis grade 3, in the presence of criteria 5 or 6)(Figure 
1) In addition to this inflammatory score, the presence of intestinal metaplasia, dysplasia or 
neoplasia was recorded. 
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Statistics 
In order to assess the association between histological inflammation and stasis, we applied 
a logistic regression model with random effect to correct for the fact that in each patient a 
different number of biopsy samples were taken. We assumed an autoregressive correlation 
structure between measurements within a patient applying Proc Genmod with the repeated 
statement in SAS 8.2. Correction for age, which had a significant effect, was made. The effect 
of smoking behaviour was not significant and therefore no correction was made in a group 
with a surprisingly low number of smoking patients. To assess the association between mi-
croscopic and macroscopic inflammation we used this logistic regression model in a similar 
way. P-values < 0.05 were considered significant.   
RESuLTS
Between 1975 and 2003, 331 patients (160 male, mean age 50.3 yrs, range 4-92) with achalasia 
were treated with pneumatic dilatation. Seventy-two patients (22 %) were excluded from this 
analysis for reasons of missing data (n= 37), or because biopsy sampling was not performed 
(n= 35). In total, 259 patients were included in the final analysis. A total of 1238 biopsy sample 
figure 1: Esophageal biopsy samples, H-E-stained; all magnifications 20 x objective except (4): 10 x objective. (1) Epithelial hyperplasia, 
elongation of papillae and dilated vascular spaces (esophagitis grade 1). (2) Intraepithelial inflammatory infiltrate with an occasional eosinophil 
(esophagitis grade 2). (3) Granulation tissue (esophagitis grade 3). (4) Erosion and ulceration (esophagitis grade 3) 
1
3
2
4
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sets (containing 4333 biopsy specimens) had been obtained from these patients, 111 sample 
sets were excluded from the analysis because the slides could not be found in the archive 
(n=25), the slides were technically not evaluable (n=3), in the slides no squamous epithelium 
or intestinal metaplasia or carcinoma was present (n=59), or a missing endoscopic report 
(n=24). In 25 sample sets, no squamous epithelium was present and therefore inflammation 
could not be assessed but there were signs of intestinal metaplasia or carcinoma. In total, in 
1102 samples from 251 patients sufficient squamous epithelium allowed histological assess-
ment of inflammation and the corresponding endoscopic report was available. The mean 
follow-up of these patients was 8.4 years (range 1 - 26). A mean of 4 sample sets per patient 
had been obtained over time (range 1 - 17). 
One hundred-sixty-five (65,7 %) patients had no endoscopic signs of esophagitis through-
out the observation period. 55 (21,9 %) showed endoscopical esophagitis grade A, 17 (6,8 %) 
grade B, 9 (3,6 %) grade C and 5 (2 %) showed grade D. Twenty-five (10 %) patients developed 
endoscopical signs of a segment of columnar epithelium in the distal esophagus suggesting 
Barrett’s metaplasia. In 13 (5%) patients, a solitary ulcer was seen at least at one occasion 
during follow-up.
Histological signs of esophagitis were scored according to the highest level of inflamma-
tion per patient during follow-up. Chronic active or ulcerating esophagitis (grade 2 (n=49) 
or 3 (n=60)) was found in 109/251 (43.4%) patients during follow-up. Chronic esophagitis 
(grade 1) was seen in 139 (55.4%) patients and only 3 (1.2%) patients had no inflammation 
(grade 0) during follow-up. After a mean of 12 years of follow-up (range 7 – 17) fifty percent 
of the patients developed moderate to severe inflammation (being grade 2 or 3) in the biopsy 
samples. (Figure 2) 
Low-grade dysplasia (LGD) in squamous cell epithelium developed in 11/251 (4.4%) pa-
tients after a mean follow-up of 6 years (range 0-12) after pneumatic dilatation and 14.5 years 
(range 9-29) after the start of symptoms. One of these patients developed squamous cell 
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figure 2: probability of survival without moderate to severe esophagitis as assessed by histology in years after the first dilatation series (1) 
and after first (2) and second (3) retreatment because of symptom recurrence. 
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carcinoma 33 year after the start of symptoms, whereas 1 patient developed carcinoma in 
situ 29 years after the start of symptoms. Squamous cell carcinoma developed in 7/251 (2.8%) 
patients after a mean follow-up of 20.4 years (range 2-33) after the start of symptoms and 10 
years (range 1-23) after the initial treatment. 
Barrett’s metaplasia (defined as the presence of intestinal metaplasia) was histological 
detected in 37/251 (14.7%) patients after a mean follow up of 6.0 years (range 0-28) after 
initial treatment. From these 37 patients, 12 (32.4%) developed LGD, 1 high-grade dysplasia 
and 3 patients adenocarcinoma. 
The estimated predicted value for the presence of histological inflammation in the pres-
ence of endoscopic esophagitis was only significant for grade B-D (p = 0.0013). In 28/53 
(52.8%) of the samples, taken from an esophagus with endoscopic esophagitis grade B, C or 
D, histological inflammation grade 2 or 3 was found. However, 156/895 (17.4%) of the biopsy 
samples obtained from patients without endoscopic esophagitis also showed grade 2 or 3 
inflammation. (Table 1, Figure 3)
Inflammation
Esophagitis Odds ratio 95% Confidence interval p-value
None 1.0
Grade A 1.43 0.86 – 2.38 0.17
Grade B t/m D 3.92 1.71 – 9.01 0.0013
Table 1: Prediction of histological inflammation with upper and lower confidence limit in the absence of endoscopical signs of esophagitis (0) 
and in the presence of esophagitis grade A (1) and esophagitis grade B, C and D (2)
figure 3: Prediction of moderate to severe (grades 2 and 3) histological inflammation (%) with upper and lower confidence limit in the 
absence of endoscopical signs of esophagitis (0) and in the presence of esophagitis grade A (1) and esophagitis grade B, C and D (2)
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Assuming the histological investigation as the gold standard for the assessment of inflam-
mation, the sensibility and specificity of endoscopy for esophagitis was 37.6 % (range 31 – 44) 
and 83.6% (range 81 – 86) respectively. 
The odds ratios showed a significant association between food stasis and the grade of 
histological inflammation, which was also present after correction for age and number of 
samples per patient. With increasing severity of food stasis during endoscopy, the odds ratio 
increased up to 4.5 in case of severe stasis (p<0.0001). (Table 2, Fig 4) 
In this study, which started in 1975, different acid suppressive therapies were used, usu-
ally for short periods after diagnosing esophagitis at endoscopy. In almost all cases, these 
therapies had been withdrawn long before the next surveillance endoscopy was performed 
and individual patients used different kinds of acid suppressive therapies during follow-up. 
We analysed the data of medication use, which was recorded in the medical chart. If there 
was no information regarding medication, we assumed no acid lowering medication was 
Inflammation
Stasis Odds ratio Confidence limits P-value
0 1.0
1 1.57 1.00 – 2.46 0.049
2 2.58 1.45 – 4.59 0.0012
3 4.50 2.57 – 7.90 <0.0001
Table 2: Prediction of histological inflammation with upper and lower confidence limits when there is no 
stasis (0), mild stasis (1), moderate stasis (2) and severe stasis (3)
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figure 4: Prediction of moderate to severe (grades 2 and 3) histological inflammation (%) with upper and lower confidence limits in patients 
who either have no food stasis (0), mild stasis (1), moderate stasis (2) and severe stasis (3)
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taken. We made a distinction between proton pump inhibitors (ppi), H2- antagonist and other 
(mostly topical) medication.  
Sixty-eight (27%) patients used acid suppressive therapy at any time during a follow-up 
endoscopy, thus 243 (22%) of the 1102 endoscopies were performed while the patient was 
using acid suppressive therapy (89 endoscopies in 32 patients during PPI treatment, 81 
endoscopies in 30 patients during H2-antagonists, and 73 endoscopies in 35 patients during 
other treatment). Patients taking acid lowering therapy other than PPI’s or H2-antagonists 
showed significantly more inflammation grade 2 and 3 than the untreated group (34 versus 
18%, p=0.001). The difference in prevalence of inflammation grade 2 and 3 between the 
patients on PPI’s or H2-antagonists versus the untreated patients was not significant (17% 
and 26% versus 18%; p=0.720, resp 0.110)  
dISCuSSIOn
The treatment of achalasia aims at reduction of the LES-pressure to relieve dysphagia. This 
is usually achieved by pneumatic dilatation or myotomy, techniques which may induce 
significant sphincter insufficiency. Gastro-esophageal reflux, which may result from this 
insufficiency, is able to cause esophagitis. On the other hand insufficient treatment of the 
non-relaxing sphincter may lead to stasis of food, which can also predispose to esophagitis. 
This intricate balance suggests that esophagitis is likely to be a common condition in acha-
lasia patients, yet there has to our knowledge no data regarding this issue been published.   
Our results show that chronic active esophagitis is indeed very common in achalasia pa-
tients after dilatation therapy. In our series, nearly all patients showed histological evidence 
of chronic esophagitis. Most of them showed active inflammation with erosive histological 
lesions, and these lesions largely remained unchanged over time. The prevalence of inflam-
mation was lower when judged by endoscopy, however also endoscopy showed macroscopic 
evidence of esophageal inflammation in a considerable proportion of patients. Thirty-six 
percent of patients showed macroscopic signs of esophagitis, being grade B to D in 12% of 
them. The sensitivity of endoscopy to detect inflammation of the esophageal mucosa is low, 
which among others, can be explained by limitations of endoscopical inspection in patients 
with often mucosal adherence of food, even after fasting. We applied the Los Angeles classifi-
cation because of its widespread application and usefulness in clinical practice, even though 
this classification was not primarily developed for patients with food stasis and achalasia.
It is difficult to differentiate between inflammation caused by acid reflux or food stasis. It 
is well known that achalasia patients even at first presentation prior to therapy can complain 
of heartburn 16, 17. The etiology of which is still unclear. The histological picture did not allow 
a clear differentiation and therefore we differentiated by endoscopy on the basis of the pres-
ence of food stasis on one hand versus esophagitis without evidence of food stasis on the 
other.
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Stasis of food is common in achalasia patients, also after dilatation treatment. This condi-
tion is often neglected as irrelevant when not accompanied by deterioration of symptoms. 
We however observed a significant association between stasis of food and the histological 
presence of inflammation. Chronic stasis is thought to contribute to mucosal hyperplasia, 
which can be complicated by multifocal dysplasia. This may after many years give rise to an 
increased risk of developing a squamous-cell carcinoma 11. Together, this warrants a more 
active approach towards achalasia patients with persisting moderate or marked stasis of 
esophageal contents. In order to reduce chronic inflammation and its complications, patients 
with chronic stasis or eroding ulcerative esophagitis may require repeated dilatation treat-
ment or myotomy, probably even independent of their reported symptoms. The association 
between symptoms, esophagitis and stasis is only moderate. Patients with achalasia tend to 
underreport their symptoms, because they are used to an often long-standing situation of 
dysphagia and interpret a slight improvement in esophageal emptying as already a dramatic 
improvement 3, 18.  Besides, many achalasia patients, especially those who are older have an 
altered vagal afferent response leading to a diminished perception of pain 19, 20. 
In order to detect inflammation, surveillance endoscopy with adequate biopsy sampling 
is necessary. The interval between the surveillance endoscopies needs further investigation 
and this may be dependent on the level of inflammation. The importance of grade 1 inflam-
mation (basal layer hyperplasia, elongation of papillae and dilation of papillary vascular 
spaces) which occurred in nearly all our patients is likely to be limited. But when more severe 
inflammation such as histological grade 3 (granulation, ulceration) remains present despite 
adequate therapy, more intensive surveillance should be offered, probably every year start-
ing 10 years after the onset of symptoms, when it is known that the risk of developing a 
carcinoma is increasing21, 22. Since surveillance endoscopies can be technically very difficult in 
achalasia patients, we should prescribe a three-day liquid diet before the endoscopy to allow 
better inspection of the esophageal mucosa. During endoscopy, the use of lugol-staining 
may help to identify high-risk lesions and allow directed biopsy sampling 23. When LGD is 
detected during endoscopy, surveillance intervals should be intensified and in case of HGD 
we suggest esophagectomy because of the frequent multifocal character of the dysplasia 7.
Our study did not provide an answer to the question whether a symptomatic relapse of 
achalasia affects esophagitis. This limitation was due to the fact that in a great proportion 
of our patients no samples were taken at the time of symptom relapse and mostly these 
relapses occurred between surveillance intervals.
There was no significant difference in inflammation between patient using PPI’s or H2 
antagonists and the patients without acid lowering therapies. However we analysed the data 
of medication use as recorded in the medical chart. If there was no information regarding 
medication, we assumed no acid lowering medication was taken, which may be a wrong 
conclusion. Besides different kinds of acid-lowering therapies were used for usually small 
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periods in our patient groups and individual patients used different kinds of acid suppressive 
therapies during follow-up.  
COnCLuSIOnS
Our study shows that esophagitis is a very common condition in patients with achalasia. 
Almost all patients with achalasia treated with pneumatic dilatation develop chronic esopha-
gitis during follow-up. The sensitivity of endoscopy for assessment of esophagitis in these 
patients is poor, but there is a significant association between endoscopic signs of food stasis 
and the presence of esophagitis. The latter may lead to hyperplasia, dysplasia and develop-
ment of squamous cell carcinoma. For this reason, the presences of food stasis or histological 
esophagitis grade 3 forms in our opinion an indication for retreatment by pneumatic dilata-
tion or myotomy even in the absence of deterioration of symptoms. 
This warrants a more active approach in the follow-up of patients with achalasia and 
requests for surveillance endoscopy with biopsy sampling in patients with achalasia after 
treatment with pneumatic dilatation to evaluate stasis and inflammation in biopsy samples.
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ABSTRACT
Introduction: Achalasia patients are considered at increased risk for esophageal cancer, but 
the reported relative risks vary. Identification of this risk is relevant for patient management. 
We performed a prospective evaluation of the esophageal cancer risk in a large cohort of 
achalasia patients with long-term follow-up.
Methods: Between 1975 and 2006 all patients diagnosed with primary achalasia in our hos-
pital were treated and followed by the same protocol. After graded pneumatic dilatation, all 
patients were offered a fixed surveillance-protocol including GI endoscopy with esophageal 
biopsy sampling.  
Results: We surveyed a cohort of 448 achalasia patients (218 men, mean age 51 yrs at diag-
nosis, range 4 to 92 years) for a mean follow-up 9.6 years (range 0.1 – 32). Overall 15 (3.3%) 
patients (10 men) developed esophageal cancer (annual incidence 0.34 (95% confidence in-
terval 0.20-0.56)). The mean age at cancer diagnosis was 71 years (range 36-90) after a mean 
of 11 years (range 2 – 23) following initial presentation, and a mean of 24 years (range 10 
- 43) after symptom onset. The relative hazard rate of esophageal cancer was 28 (confidence 
interval 17 – 46) compared with an age- and sex- identical population in the same timeframe. 
Five patients received a potential curative treatment.
Conclusion: Although the gastro-esophageal cancer risk in patients with longstanding acha-
lasia is much higher than in the general population, the absolute risk is rather low. Despite 
structured endoscopical surveillance, most neoplastic lesions remain undetected until an 
advanced stage. Efforts should be made to identify high risk groups and develop adequate 
surveillance strategies.
KEy wORdS: 
esophageal achalasia, therapy, pneumatic dilation, malignancy, esophageal cancer, surveil-
lance, Barrett’s esophagus, adenocarcinoma, squamous cell cancer.
Study highlights:
1  What is current knowledge: Achalasia may be a risk factor for esophageal cancer 
development. Surveillance is debated.
2  What is new here:In our large cohort with long term follow-up, the relative hazard rate 
for development of esophageal cancer in achalasia patients was 28. Despite regular 
surveillance with 1- to 3- years intervals, most cancer are detected in advanced state
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InTROduCTIOn
 Achalasia is a rare, chronic esophageal motility disorder with an estimated annual preva-
lence of 1 per 100,000 subjects in the western populations. The disease can occur at all ages 
but the incidence seems to increase with age. Predominant symptoms are dysphagia and 
regurgitation, due to the impaired relaxation of the lower esophageal sphincter (LES) and 
the loss of normal peristalsis. Treatment is purely symptomatic as the etiology of achalasia 
is still unclear. Treatment aims at lowering of the LES-pressure to  improve the passage of 
food 1. Adequate treatment with sufficient symptom control does not prevent that patients 
suffer from persistent esophageal distension with retention of foods and fluids, bacterial 
overgrowth and impaired clearance of regurgitated acid gastric contents. These factors can 
lead to chronic inflammation of the esophageal mucosa, which potentially increases the risk 
of development of hyperplasia, dysplasia and esophageal cancer 2, 3. In contrast, lowering of 
LES-pressure can aggravate acid gastro esophageal reflux leading to Barrett’s metaplasia4 
and adenocarcinoma 5-7. 
The relationship between achalasia and esophageal carcinoma has been studied before. 
Three studies did not observe esophageal cancer in achalasia patients 8-10. However, these 
follow-up studies contained rather low numbers of evaluable cases (91 and 162 respectively) 
and had a limited follow-up of 10 years or less. Another study including 253 patients found 
no significant difference in 20 year survival rate between achalasia patients and controls11 
In contrast, other investigators reported an increased risk for development of esophageal 
cancer, but the results of these studies nevertheless varied widely. Again, some of these 
studies were limited in follow-up 12-14 or patient numbers 15.  The largest cohort follow-up 
study however reported on 1318 patients with achalasia followed for 17 patient-years. This 
study revealed a sevenfold increased risk for esophageal cancer compared to the general 
population 16. Another study conducted in Sweden included 1,062 patients followed for 9,864 
patient years and found a sixteen fold increased esophageal cancer risk17.  In addition to 
these cohort studies, autopsy studies reported 20-29 % of patients with achalasia having 
esophageal cancer at death 18-20. Altogether, the reported relative risk for esophageal cancer 
varied between zero and 140. This variation may be due to differences in study design (cross 
sectional versus follow-up), numbers of patients and length of follow-up. Also, patients with 
pseudo-achalasia due to esophageal or gastric cancer were not always excluded and most 
studies did not mention other risk factors for developing esophageal squamous cell carci-
noma such as alcohol and nicotine use.
Despite these conflicting data achalasia of the esophagus is generally accepted as a condi-
tion with an increased risk of particularly squamous cell carcinoma, which raises the question 
whether surveillance is needed and useful. 
Without surveillance, achalasia patients with esophageal carcinoma usually present in an 
advanced stage with poor prognosis. This is enhanced by the fact that achalasia patients are 
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used to delayed esophageal emptying and only report worsening of these symptoms due 
to development of an obstructive tumor at a late stage 21. Little data exist concerning the 
benefit of surveillance, but so far, this does not seem cost -effective nor to improve prognosis 
13, 15, 21, 22. The most recent American Society for Gastrointestinal Endoscopy guidelines do not 
recommend routine endoscopic surveillance in the absence of more convincingly supportive 
data23.
We performed a large prospective study (with 448 patients and 4,483 patient years of 
follow-up) with strict follow-up to determine the incidence of esophageal carcinoma and to 
evaluate the efficacy of long-term endoscopical surveillance.
PATIEnTS And METhOdS
Study patients
This single centre cohort study was performed in a university hospital covering the south-
west of the Netherlands, an area with approximately 4 million inhabitants. The hospital 
serves as a third referral centre for patients with benign and malignant esophageal disorders. 
This includes referral of patients suspected to suffer from achalasia for diagnostic work-up, 
treatment, and follow-up. Since 1975 all patients referred with such a suspicion of achalasia 
were evaluated and treated by a selected number of physicians according to a strict protocol, 
which did not change during follow-up (see below). Every patient diagnosed with primary 
achalasia in the period of 1975 to 2006 was included in this study. 
The diagnostic process included a medical history with special attention to duration of 
symptoms, physical examination, esophageal manometry, timed barium esophagram and 
upper gastrointestinal endoscopy.
Treatment 
Once the diagnosis of primary achalasia was established, all patients with substantial com-
plaints (in general Eckardt score of three or more) were offered treatment. The Eckardt score 
consists of three items: dysphagia, regurgitation, and chest pain. For each item a score of 0 
(none), 1 (occasional), 2 (daily), or 3 (each meal) is made generating an overall score between 
0 and 9 points24.  From 1974 till 1976, homemade pneumodilators were used. Since then, 
dilation balloons became commercially available and these procedures were carried out with 
the use of a Rigiflex balloon (Boston Scientific, Natick, MA, USA).
Baseline dilatation was performed on 3 consecutive days with balloons of either the same 
or incremental (30, 35, and 40 mm) diameter. Under conscious sedation the balloon was 
positioned fluoroscopically at the gastro-esophageal junction and inflated to a pressure of 
300 mm Hg for 1 minute. 
Recurrences were treated by pneumatic dilatation or in case of an early or repeated recur-
rence by laparoscopic myotomy combined with a fundoplication.
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Surveillance
Every patient was offered surveillance according to the same protocol. This follow-up proto-
col was approved by the local institutional review board, patients consented to inclusion and 
structured follow-up.
Three months after pneumatic dilation, symptoms and body weight were recorded and 
an esophageal manometry and timed barium esophagram were repeated. These procedures 
were repeated after one, two, four, and seven years, together with an upper gastrointestinal 
endoscopy including careful inspection and standardized biopsy sampling (at least 4 speci-
mens taken a few cm above the gastro-esophageal junction and extra samples from suspi-
cious lesions) for detection of inflammation, dysplasia, metaplasia or malignancy. Further 
follow-up after a 7-years recurrence free interval consisted of a repeated 3-yearly interview 
and upper endoscopy with biopsy sampling.
When patients were considered too old, suffered from severe co-morbidity or simply re-
fused surveillance endoscopies, they were once yearly followed by telephone-calls to obtain 
maximal follow-up information. When a Barrett’s esophagus was identified (in 8% of the 
patients) they were offered a Barrett’s surveillance protocol. 
Statistical analysis
Data on the incidence of esophageal carcinoma for men and women in the general popula-
tion of the Netherlands could be obtained for the period 1988 until 2006 from the national 
cancer registry. For the period before 1988 only data from one region in the Netherlands 
was available; this region did not show substantial differences with the rest of the Nether-
lands with respect to the incidence of esophageal carcinoma after 1988. The years at risk for 
every patient in the cohort were defined. Incidences for the population at risk and for the 
general population were characterized by categorical variables for age class, gender, period 
and whether it concerned achalasia patients or the general population. The estimated effect 
for the last, dichotomous, variable was transformed to a hazard ratio. Confidence limits and 
significance of p-values were chosen to be at the 95% level. To perform this analysis we used 
S-Plus ® 7.0 for windows, 1988-2005 Insightful Corp (Seattle, WA). The difference in response 
to dilation therapy between the patients who developed cancer and the patients who didn’t 
develop cancer was computed with a Fisher exact test 2-sided and a chi square test was used 
to compute differences in food stasis at endoscopy and esophageal widening at barium con-
trast esophagraphy between the two groups of patients (SPSS 13.0 for windows, Chicago, IL).
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RESuLTS
Over the period 1975-2006 a total of 448 patients (218 male, mean age 50.9 years) were 
diagnosed with primary achalasia (table 1). 
Two patients presenting with a gastro-esophageal malignancy within the first year of FU 
after start of symptoms were excluded, based on the likelihood that the dysphagia symptoms 
were caused by the cancer (secondary achalasia instead of primary achalasia).
In addition three other patients were excluded because they were diagnosed with acha-
lasia and esophageal carcinoma at the same time. At the time of diagnosis they appeared to 
have had achalasia symptoms for many years. This means that they have no time at risk for 
developing cancer while being diagnosed with achalasia. It is possible these patients would 
never have been diagnosed with achalasia if they didn’t develop esophageal carcinoma. Any 
similar patient not seeking help for achalasia symptoms would not end up in the control 
group of achalasia patients not developing esophageal cancer.
The mean follow-up was 15 years (range 0.1 – 61) after start of symptoms and 9.6 years 
(range 0.1 – 32) after diagnosis of achalasia. This large difference in follow-up is related to the 
time of inclusion in the cohort. By 2006 one-hundred patients (52% women) had died from 
non-achalasia related causes after a mean follow up of 8 yrs (0-22) following diagnosis and 
at a mean age of 80 yrs (54-96). A total of 94 patients (56% women) were lost to follow-up 
after a mean follow-up of 6 yrs (0-22) following diagnosis and at a mean age of 56 yrs (20-88) 
(table 1). 
Four-hundred and eight (91%) patients were treated with graded pneumatic-dilation. Six 
(1%) patients were operated without previous dilatation, one elderly patient was treated with 
botulin toxin, and 33 (7%) patients were not treated until end of follow-up. Sixty-eight (15.1 
Esophageal cancer Total group achalasia patients
Number of patients 15 448
Gender M:F (n) 10:5 218:230
Delay (years) 13 (1-36) 5.6 (0-30)
Age diagnosis achalasia 61 (31-87) 51 (4 – 92)
Age diagnosis esophageal cancer 71 (36-90)
Number of patients receiving Single treatment: 
repeated treatment
9:6 287:121
Mean follow-up after first symptoms (years) 24 (10-43) 15 (0- 61)
Outcome: (n)
     Lost
     Death
     In surveillance
94
100
239
Table 1 Patient characteristics
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%) patients had received previous treatment before referral but they nevertheless presented 
with persistent symptoms and were dilated again. 
A total of 4,483 person years at risk were observed in this study. The expected rate of 
esophageal cancer using the incidence figures of the regional cancer registration would be 
12 per 100,000 specific for the age, gender and calendar year. Therefore, we could expect 0.54 
patients with esophageal cancer in our cohort.
During follow-up, 15 (3.3%) patients (10 men) developed esophageal cancer (3 adeno-
carcinoma in Barrett’s metaplasia and 12 squamous cell carcinoma). The mean age at initial 
presentation with achalasia was 61 years (range 31-87) after a mean duration of symptoms of 
13 years (range 1-36). The mean age at diagnosis of esophageal cancer was 71 years (range 
36 – 90). Esophageal cancer was diagnosed a mean of 11 years (range 2 – 23) after initial pre-
sentation and a mean of 24 years (range 10 – 43) after symptom onset (table 1). The Kaplan 
Meier curve (Figure 1) shows the development of cancer after achalasia diagnosis.
The observed incidence rate was 335 (confidence interval 202 - 555) per 100.000 person 
years. The hazard ratio for achalasia patients to develop esophageal cancer was 28 (confi-
dence interval 17 - 46) in our cohort.
All cancer patients were Caucasian. Only two of them had a history of smoking, none of 
them had a history of alcohol abuse, nor had any of them suffered from lye ingestion. The 
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figure 1: Cumulative incidence of esophageal cancer (y-axis) after diagnosis of achalasia (in months, x-axis). The risk of development of 
esophageal cancer increased from less than 1% five years after the diagnosis of achalasia to approximately 4% and 10% after 10 and 20 years 
respectively.
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prevalence of esophageal dilatation at baseline recorded with timed barium esophagram 
was equal in the patients who developed cancer compared with the controls computed with 
a chi-square test (p= 0.630). Also food stasis recorded at the first endoscopy was no predictor 
for cancer risk during follow-up (p = 0.299).
Medication use was also studied but was no predictor for cancer risk, which can among 
others be related to the fact that individual drugs were often prescribed for a limited period 
and medication changes occurred frequently. 
In our total cohort, 278 (71 %) patients had a persistent remission after one series of three 
pneumatic dilations. Of the 15 patients with esophageal carcinoma, treated with pneumatic 
dilatation, pneumatic dilation had been successful in 9 patients (60 %, p=0.39, n.s. (Fisher’s 
exact test two-sided)), 5 had needed a second series of dilations and one a third. 
At the time of cancer diagnosis, ten patients were still under endoscopical surveillance. 
In five patients, the surveillance had been stopped at an earlier stage for reasons of age, 
co-morbidity, or patient preference; they were interviewed annually by telephone. All 
esophageal carcinomas were diagnosed in targeted biopsy samples.
Five patients (all diagnosed with cancer during a surveillance endoscopy) were treated 
with esophageal resection. Following surgery, two patients had a long disease-free survival 
(>8 and >10 years), one patient died 4 years later due to a non-related disorder, and one 
patient developed metastases 6 years later. The fifth patient died of recurrent cancer within 2 
years after resection. The remaining 10 patients received palliative care because they were di-
agnosed with advanced disease (n=6), or had severe co-morbidity precluding surgery (n=4).
dISCuSSIOn
The first relation between achalasia and esophageal carcinoma was reported in 1872. Since 
then, there have been several case-reports and studies conducted on this subject with con-
troversial results against a background of often small patient numbers and limited length of 
follow-up. Esophageal cancer may arise as a result of chronic food stasis leading to chronic 
inflammation, epithelial hyperplasia, multifocal dysplasia and eventually squamous cell car-
cinoma (SCC) 2, 25, 26. An alternative pathway may occur after adequate dilation therapy of the 
lower esophageal sphincter, provoking gastro-esophageal reflux, Barrett esophagus (BE) and 
adenocarcinoma (AC) 5, 6, 27. Either of these routes may take decades. Therefore malignancies 
tend to occur no sooner than 15-20 years after first achalasia symptoms, and studies with 
shorter follow up may underestimate the malignancy risk. This estimate was in many studies 
further challenged by reports on follow-up from time of diagnosis instead of from time of 
symptom onset, which despite all uncertainty of reporting is likely to be more relevant for the 
purpose of cancer risk estimates.
Our cohort had a mean follow-up of 15 years (range 0-61) after first achalasia symptoms. 
The cancer patients in this cohort developed their malignancy after a mean of 24 (10-43) 
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years after the onset of achalasia symptoms (Table 1). As illustrated by the Kaplan Meier curve 
for the development of esophageal cancer, the cancer risk increased rapidly with the length 
of follow-up (Figure 1). The average delay until diagnosis of achalasia in our cohort was 5.6 
years (range 0-30), which is not dissimilar from other studies28 . Three cancer patients (not 
included in this cohort) in fact only presented when they had developed invasive esophageal 
cancer and appeared to have a fully decompensated achalasia esophagus and in retrospect 
had had achalasia symptoms for 24 to 35 years. These cases show that the individual estimate 
of cancer risk should be based on symptom duration instead of follow-up since diagnosis of 
achalasia.   
We observed 15 cases of esophageal cancer in 448 patients with a total of 4,483 patient-
years at risk, which equals an incidence rate of 335 (confidence interval 202-555) per 100,000 
per annum (0.34%) and a hazard ratio of 28 (confidence interval 17-46).  This equals the an-
nual incidence to develop gastric cancer in case of gastric intestinal metaplasia or atrophic 
gastritis29 and is slightly lower than the reported annual incidence of Barrett’s carcinoma in 
Barrett’s esophagus of 0.5 – 1.0 %30. Surveillance in Barrett’s esophagus is generally accepted 
and surveillance is in some countries advocated for intestinal metaplasia of the stomach and 
atrophic gastritis. Similarly, surveillance in achalasia could be propagated. 
The number of patients lost to follow-up is relatively high. These lost patients were not 
treated for esophageal carcinoma in our hospital but it is possible that they developed 
malignancy and were treated in another hospital. The patients who died of other causes also 
had a shorter follow-up but were relatively old. The total number of years at risk of our cohort 
was large and allowed a reliable comparison with the general population. As patients lost 
to follow-up did not differ in any major aspect (age, sex, duration of achalasia, prevalence of 
esophageal dilatation and food stasis) to those who completed follow-up, there is no reason 
to assume different esophageal cancer incidence in the lost-to-follow up patients, and thus a 
different relative cancer incidence.  
Apart from disease duration, one may hypothesize that the efficacy of LES dilation therapy 
may also affect the risk for esophageal cancer in achalasia. Efficacious therapy aims to reduce 
food stasis, which might interrupt the progression to carcinoma and thus reduce the squa-
mous cell cancer risk. Data about the relationship between dilation therapy and squamous 
cell cancer risk are however scarce. In our total cohort, 71 % of patients had a persistent 
remission after one series of three pneumatic dilations. Of the 15 patients with esophageal 
carcinoma, treated with pneumatic dilatation, pneumatic dilation had been successful in 9 
patients (60 %, p=0.39, not significant (Fisher’s exact test 2-sided)). Therefore, in our study 
the efficacy of therapy did not appear to influence the malignancy risk. None of the 15 cancer 
patients had been treated with a myotomy and/or fundoplication. In total, only 26 patients 
were operated and therefore our results do not allow any calculation on the potential effect 
of myotomy of fundoplication on esophageal cancer risks. 
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Another argument to perform surveillance is the fact that esophageal malignancies in 
achalasia patients are often detected late and in an advanced stage, because symptoms 
of obstructive cancer mimic the presenting symptoms of achalasia 21. However a 3-yearly 
surveillance could, in our series, not prevent that 6 of ten patients under surveillance (60%) 
died of esophageal cancer within 2 years. This mortality risk resembles the mortality risk of 
esophageal cancer in the general population but is in contrast with the reported survival of 
Barrett’s adenocarcinoma diagnosed by surveillance of 73 – 85% 31, 32 . An explanation could 
be that in Barrett’s esophagus the whole segment at risk is relatively small and is more easily 
mapped by endoscopy and biopsy sampling than in cases with achalasia. Another difference 
is the difficult inspection in achalasia patients due to mucosal food adherence.  
These facts raise the question if long-term surveillance in achalasia is useful and if so 
how it should be performed. We used a follow-up protocol for early detection of symptom 
recurrence, reflux esophagitis, as well as progression towards neoplasia. Patients underwent 
manometry, timed esophagraphy and endoscopy with biopsy sampling 1, 2, 4 and 7 years 
after pneumatic dilation and after 7 years at least every 3 years. In case of dysplasia or severe 
inflammation the interval was shortened. During every endoscopy random biopsies of the 
distal esophagus were taken together with targeted biopsies from mucosa with suspect ap-
pearance. Probably surveillance may possibly be improved by the use of specific histological 
markers 33 or the aid of lugol staining 34 The surveillance time interval of three years is chosen 
at the beginning of the protocol in 1975 and was based on the limited data of esophageal 
carcinoma in achalasia and the lack of data on the effect of surveillance on survival.
A last argument against surveillance is cost efficacy. The low cancer incidence requires 
many investigations to detect one cancer, and nevertheless many of these malignancies 
remain to have a very poor prognosis, together leading to high costs per life-year saved.
Therefore, when combining the pros and cons it seems useful to define high risk patients 
and to develop a tailor-made surveillance program which starts 10 years after first achalasia 
symptoms, with a shorter interval than the 3 years used in our series and probably a different 
technique. Known risk factors for squamous cell cancer such as male gender, age over 60 
years, cigarette smoking, and alcohol use probably should be taken into account and perhaps 
advance surveillance to earlier years. In the cohort a very low number of patients smoked 
(13%) or drank more than 2 units alcohol a day (2%). This prevented us from finding any 
relation between smoking and alcohol intake on esophageal cancer incidence in our cohort. 
To enhance the accuracy of endoscopic surveillance, patients can be kept on a liquid diet 
for 24 to 48 hours prior to endoscopy and be treated with additional esophageal lavage if 
food retention or stasis compromises a clear view at endoscopy. These issues and the use of 
histological markers in the biopsy samples, as well as more advanced endoscopic imaging 
methods need to be further studied as esophageal cancer remains an important threat for 
patients with long existing achalasia.
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COnCLuSIOn
The relationship between achalasia and esophageal cell carcinoma is established with an 
incidence rate of 0.34 % per year of follow up. This annual incidence rises with length of 
follow-up and is much higher after 20 years of follow-up (Figure 1).  Although the absolute 
risk is low this is significantly increased compared to the general population (hazard ratio 
28). The prognosis of patients with achalasia and esophageal carcinoma remains poor, even 
when they were under regular endoscopic surveillance. To improve this prognosis, we should 
define high-risk achalasia patients and keep them under more frequent, probably annual 
endoscopic surveillance starting 10 years after symptom onset. In combination with known 
other risk factors the surveillance may be started earlier. More studies are needed to establish 
the optimal screening interval and technique.
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ABSTRACT
Background: Achalasia is characterized by esophageal a-peristalsis and impaired relaxation 
of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing 
to gastro-esophageal reflux and Barrett’s esophagus (BE). The co-incidence of achalasia and 
BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, BE development 
and esophageal adenocarcinoma. 
Aims: To determine the incidence of BE and esophageal adenocarcinoma in achalasia pa-
tients treated with PD. 
Methods: We performed a single-center cohort follow-up study of 331 patients with achalasia 
treated with PD. Mean follow-up was 8.9 years consisting of regular esophageal manometry, 
timed barium esophagram and endoscopy.
Results: Twenty-eight (8.4%) patients were diagnosed with BE, one at baseline endoscopy. 
This corresponds with an annual incidence of BE of 1.00 % (95% CI 0.62-1.37).  Hiatal herniation 
was present in 74 patients, 21 developed BE compared to 7 of 257 patients without a hiatal 
hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop BE if a hiatal hernia was 
present. Post-treatment LES pressures were lower in patients with BE than in those without 
(13.9 vs. 17.4 mm Hg; p=0.03). Two (0.6%) patients developed esophageal adenocarcinoma 
during follow-up.
Conclusion: BE is incidentally diagnosed in untreated achalasia patients despite high LES 
pressures, but is more common after successful treatment especially in the presence of hiatal 
herniation. Patients treated for achalasia should be considered for GERD treatment and sur-
veillance of development of BE, in particular, when they have low LES pressures and a hiatal 
herniation.
KEywORdS: 
achalasia, Barrett’s esophagus, gastro-esophageal reflux, esophageal adenocarcinoma, hiatal 
hernia.
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InTROduCTIOn 
Achalasia and Barrett’s esophagus are generally thought to be the opposing ends of the spec-
trum of esophageal disease, although both relate to malfunctioning of the lower esophageal 
sphincter (LES). Achalasia is a rare neuro-degenerative disorder with an annual incidence of 1 
per 100,000 inhabitants 1. It is characterized by a-peristalsis of the esophageal body and high 
basal LES pressure without a swallow-induced relaxation of the LES. Predominant symptoms 
of achalasia are dysphagia and regurgitation, often accompanied by weight loss. 
In contrast, Barrett’s esophagus is a more common condition with increasing prevalence 
up to 1.6 percent 2-5. Barrett’s esophagus is characterized by the replacement of normal squa-
mous cell epithelium by specialized intestinal columnar epithelium. Patients with Barrett’s 
esophagus have an increased risk to develop esophageal adenocarcinoma 6. Although the 
exact etiology of Barrett’s metaplasia is incompletely understood, there is a clear relationship 
with gastro-esophageal reflux disease (GERD) 7. In contrast to achalasia, GERD is associated 
with hiatal hernia, low resting pressure of the LES and an increased frequency of transient LES 
relaxations, both facilitating the reflux of acid gastric contents 8. 
Treatment of achalasia aims at reducing LES pressure. This is generally achieved by surgical 
myotomy or pneumatic dilatation (PD) 9.  The effect of PD treatment depends on age, LES 
pressure three months after dilatation, obliteration of the balloon waist during dilatation and 
symptoms of classic achalasia 10. Effective therapy resulting in a low LES pressure may how-
ever lead to GERD, which in theory may predispose to Barrett’s esophagus. Few data exist on 
the incidence of GERD after treatment of achalasia, both because of the lack of performance 
of specific diagnostic procedures such as 24-hr pH monitoring after achalasia treatment and 
limited cohort follow-up data in achalasia patients. However, GERD has been reported in 
11-25% of achalasia patients following myotomy and in 2% following PD 11. Even fewer data 
exist on the development of Barrett’s esophagus in patients who underwent treatment for 
achalasia. 
We hypothesized that adequate PD treatment for achalasia may be complicated by the 
development of Barrett’s esophagus and possibly esophageal adenocarcinoma. We therefore 
studied the incidence of and risk factors for Barrett’s esophagus and the development of 
esophageal adenocarcinoma in a large cohort of achalasia patients treated with PD.  
METhOdS
Patients
Since 1975 all patients with achalasia referred to our hospital have been treated and followed 
according to a fixed protocol as described before 10. The diagnosis and treatment protocol did 
not change over time and was performed by a limited number of physicians. The diagnostic 
process included the medical history and physical examination, esophageal manometry, a 
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timed barium esophagram and an upper GI-endoscopy. During manometry a mean resting 
LES pressure was recorded as a mean of four (end-expiratory) measurements. LES relaxations 
and peristalsis of the esophageal body were studied. A timed barium esophagram was per-
formed after swallowing 200 ml barium contrast with standardized records after 0, 1 and 10 
minutes. An upper GI endoscopy was done to rule out other causes of dysphagia. Signs of 
gastro-esophageal reflux disease were noted. A hiatal hernia was diagnosed during insertion 
and only when the distance between the gastro-esophageal junction and the aperture of the 
diaphragm was more then 2 cm.
Therapy
Once a diagnosis of primary achalasia had been established or confirmed, all patients were 
offered treatment with pneumatic dilatation on three consecutive days with an increasing 
balloon diameter of respectively 30, 35, and 40 mm. The balloons were in the very early days 
home-made, with a balloon inside a linen cuff with a length of 12 cm and a fixed diameter 
of 30, 35 and 40 mm. In later years Rigiflex pneumatic dilatation balloons (Boston Scientific, 
Natick, MA, USA) were used. Dilatation was performed under conscious sedation and fluoro-
scopic control up to a pressure of 300 mm Hg. All pneumatic dilatations were over the years 
performed by a total of 3 endoscopists, experienced in pneumatic dilatation.
Follow-up
Every patient was followed according to a fixed protocol. Three months after pneumatic dila-
tation, patients were interviewed for esophageal complaints, patient’s weight was recorded, 
and esophageal manometry and barium swallow were repeated. This evaluation including 
upper gastrointestinal (GI) endoscopy was repeated after 1, 2, 4 and 7 years. 
Upper GI endoscopy included random biopsy (3-4 biopsies) sampling from the distal 
esophagus just above the gastro-esophageal junction and targeted biopsy sampling from 
any specific lesion, such as suspected Barrett’s epithelium, dysplasia or malignancy. For his-
tological examination, 4 μm haematoxylin-eosin stained routine histological sections were 
used. In case of suspected Barrett’s esophagus, four biopsies were obtained (one from each 
quadrant) of every 2 cm of columnar epithelium to assess the presence of intestinal type 
columnar epithelium. Esophagitis was diagnosed both endoscopically graded according the 
Los Angeles classification (grade A-D) and histologically. Barrett’s esophagus was endoscopi-
cally classified as short segment (<3 cm) or long segment Barrett’s esophagus. Hiatal hernia 
was assessed during introduction of the endoscope with limited inflation, and diagnosed 
when the distance between the gastro-esophageal junction (GEJ) and the aperture of the 
diaphragm was more than 2 cm. 
Further follow-up after 7 years consisted of an interview and upper GI endoscopy with 
biopsy sampling at least every 3 years. Some patients refused these interval endoscopies or 
other long-term follow up. These patients were contacted by telephone every year to check 
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on symptoms and weight loss. In case of symptom recurrence or persistence, patients were 
either retreated with pneumatic dilatation or underwent surgical myotomy, depending on 
the time of relapse, success of initial treatment and patient’s preferences10. If a patient had 
died, the cause of death was checked with the general practitioner or the civil registration.
Statistics 
The development of barrett’s esophagus and hiatal hernia were expressed as barrett’s-free 
and hiatal hernia-free survival curves, calculated by means of the kaplan meier method. The 
uni-variate effect of patient characteristics are given as hazard ratio’s estimated by cox pro-
portional hazards analyses together with the log-likelihood p-values. Statistically significant 
variables, as well as other clinically relevant variables (age, gender) were included in a multi-
variate cox’s proportional hazards analysis. By means of step-wise backward elimination, a fi-
nal model was constructed comprising variables which were significantly and independently 
(i.e. controlled for other variables) related to the endpoints barrett’s esophagus or hiatal 
hernia, respectively. As a hiatal hernia event during follow-up often was followed by develop-
ment of barrett’s epithelium, the effect of hiatal hernia on barrett-free survival was included 
in the cox’s proportional hazard model as a time-dependent covariate. For all cox models, the 
assumption of proportional hazards was investigated for each variable by studying the ln(-ln)
plot. All analyses were carried out in spss for windows, version 11.0.1 (spss, chicago, il). The 
level of statistical significance was set at a two-sided p<0.05. LES-pressures were measured 
during esophageal manometry before and after treatment, the wilcoxon signed rank test was 
applied to compare these.  
RESuLTS
Therapy
Over the period of 1975-2003, 394 patients were referred to our hospital with a clinical sus-
picion of achalasia. Fourteen patients were diagnosed with secondary achalasia caused by 
malignancy, 16 patients had a non-specific motility disorder, 5 patients had diffuse esopha-
geal spasms and in 10 patients no specific diagnosis was made. The remaining 349 patients 
were diagnosed with primary achalasia. Six (2%) of these 349 patients refused treatment 
for various reasons, another 6 were treated elsewhere, 1 preferred surgery and in 5 patients 
severe co-morbidity prohibited any treatment. 
The remaining cohort consisted of 331 patients (male/female 160/171, mean age at di-
agnosis 51 years, range 4 to 90 years). They were followed for a median period of 8.9 years 
(range 3 months to 25 yrs). Sixty (18%) patients had received previous treatment (pneumatic 
dilatation or myotomy (n=19)) before referral but they nevertheless presented with persis-
tent symptoms and were offered dilatation again. 
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All 331 patients were initially treated with PD. After this initial treatment 241 (73%) patients 
had a persistent remission of symptoms, whereas 88 (27%) patients were re-dilatated and 3 
(1%) patients were treated with myotomy because of symptom persistence or recurrence. 
Eventually during long follow up, another 13 (4%) patients underwent surgical myotomy 
after repeated dilatation. Of these 16 operated patients, 6 again had symptom recurrence 
for which treatment with pneumatic dilatation was applied. The majority of patients were 
treated immediately after the establishment of the diagnosis of achalasia. 
Most patients underwent post-treatment endoscopy, 18 (5%) patients refused routine 
follow-up endoscopy according to the protocol. During follow up 86 (26%) patients died. 
In total, 14 (4%) patients developed esophageal cancer, these included 12 patients with 
squamous cancers and 2 patients with adenocarcinoma. One of these patients was treated 
by esophagectomy and has since then a long disease free survival. The other patient first was 
diagnosed with high grade dysplasia for which she was treated with endoscopic mucosal 
resection followed by ablative therapy (photodynamic therapy). This patient developed an 
adenocarcinoma with hepatic metastases 6 years afterwards. Sixty-four (19%) patients were 
lost to follow up after a mean follow up of 6 years (range 0- 19) after PD.
Development of erosive esophagitis
Data on esophageal histology and endoscopy have been published earlier12. In brief 66% 
of patients did not develop any endoscopic signs of esophagitis during follow-up. Grade A 
esophagitis occurred in 22 % of the patients and 11 % was diagnosed with grade B-D esopha-
gitis according to the Los Angeles classification system at any time during the follow-up. 
Histological examination however showed a higher prevalence of esophagitis. 
Development of Barrett’s esophagus
Twenty-eight (8.4%) of the 331 patients were diagnosed with Barrett’s esophagus (picture 
1). This group consisted of 12 males and 16 females, all Caucasian. Their mean age when 
diagnosed with a Barrett’s esophagus was 55.9 years (range 35-84 years). One patient was 
diagnosed with Barret’s esophagus at baseline endoscopy, whereas new development of 
Picture 1: endoscopic picture of a dilated and elongated esophagus with some food retention and histologically proven Barrett’s esophagus 
with high grade dysplasia.
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Barrett’s metaplasia was observed in the other 27 Barrett’s patients. The remaining 27 (8.2%) 
patients developed a Barrett’s esophagus during follow-up at a mean interval of 67 months 
(range 6 to 224) after initial treatment with pneumatic dilatation. This corresponds with 
an annual incidence of Barrett’s esophagus in this population of 1.00 % (95% CI 0.62-1.37) 
(Figure 1). Nineteen patients had a Barrett’s esophagus less than 3 cm in length, the other 
nine had a long segment varying in length from 3 to 7 cm. The characteristics of patients 
with and without Barrett’s esophagus are listed in Table 1. Both groups did not differ with 
follow-up in years
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figure 1: Development of Barrett’s esophagus after the diagnosis of achalasia, shown as Barrett free survival in years of follow-up
Total Barrett + Barrett - hR* (95% C.I.) p-value
Number 331 28 303
Female 161 16 145 1.09 (0.51; 2.32) 0.83
Age (yr) 
mean (S.D.)
51.1 (21.4) 55.9 (15.2) 50.7 (21.8) 1.02 (1.00; 1.04) 0.06
Myotomy 35 7 28 2.5 (1.00; 6.19) 0.07
Pre LES-pressure
(mm Hg) 
median (range)
30.0 (5-207) 30.0 (10-100) 30.0 (5-207) HR≤30 = 1
HR>30 = 1.06 (0.56; 
2.44)
0.90
Post LES-pressure (mm Hg)
median (range)
15.0 (2-125) 13.5 (5-35) 15.0 (2-125) HR≤15 = 1
HR>15 = 0.46 (0.18; 
1.14)
0.07
Hiatal hernia present 14 13 1 8.04 (3.58; 18.1)# <0.001
Table 1 Characteristics of patients with and without Barrett’s esophagus and the corresponding Relative Risk‘s 
 * Hazard Ratio (HR) estimated by univariate Cox regression analysis of the 27 cases with Barrett during follow-up. The log-likelihood p-value is 
reported.
 # HR of hiatal hernia entered as a time-dependent covariate in the Cox regression analysis.
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respect to age or sex. Barrett’s esophagus tended to be more common after myotomy, but 
this difference was not significant (RR = 2.5 95% C.I [1.00; 6.19] (p = 0.07). 
Development of esophageal adenocarcinoma
During follow-up, 2/28 (7%) patients with a Barrett’s esophagus developed esophageal 
adenocarcinoma. This occurred 25 and 27 years after the initial diagnosis of achalasia, at an 
age of respectively 70 and 84 years. Both patients had started with endoscopic surveillance 
from the time of first balloon dilation onwards for a period of respectively 18 and 14 years. In 
these patients, the development of esophageal carcinoma was not preceded by the finding 
of dysplasia in the random surveillance biopsies, the last of which had been obtained one 
respectively two years prior to cancer diagnosis. 
Hiatal hernia
A hiatal hernia was present in 74 (22%) of the 331 patients. Sixteen patients were diagnosed 
with a hiatal hernia prior to PD treatment, the remaining 58 patients after PD treatment.
Twenty-one (28%) patients with a hiatal hernia developed a Barrett’s esophagus, com-
pared to 7 (2%) of the 257 patients without a hiatal hernia. Three of the 21 patients with 
hiatal hernia and Barrett’s esophagus had a hiatal hernia at the time of diagnosis of achalasia, 
years
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figure 2 Barrett free survival if no development of hiatal hernia (solid line, time is years since diagnosis of achalasia) and after hiatal hernia 
(broken line, time is years since development of hiatal hernia)
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the remaining 18 patients developed a hiatal hernia at a mean of 6 (range 1-15) years after 
PD treatment. Statistical analysis using a time-dependent Cox regression analysis revealed 
a Hazard ratio of 8.04 (95 % CI 3.5-18.1), p<0.001 to develop a Barrett’s esophagus if a hiatal 
hernia is present (Figure 2). In a uni-variate Cox regression analysis older age appeared a 
significant factor in the development of hiatal hernia, in contrast with sex, myotomy and 
LES pressure. Statistical analysis of the correlation between Barrett’s esophagus and the later 
development of hiatal hernia also showed significance (HR 8.8, 95% CI 4.32 to 17.9, p<0.001). 
The results are listed in Table 2.
LES pressures
LES pressures were measured before and after treatment. As expected for the total group of 
achalasia patients, post-treatment LES pressures were lower than pre-treatment LES pres-
sures (median 15.0 vs. 30.0 mm Hg; p<0.001, Wilcoxon Signed Rank test) indicating effective 
dilatation treatment. The LES pressures before or after treatment were not significantly 
related to development of a hiatal hernia.
Patients with a post-treatment basal LES pressures lower or equal to 15 tended to be at 
higher risk to develop Barrett’s esophagus: HR= 2.17 95% C.I. [0.88; 5.56], p=0.07 (Table 1).
Finally, a multivariate Cox’s proportional hazards analysis on the development of Barrett’s 
esophagus and hiatal hernia was performed with all clinically relevant variables as age, gen-
Total
hiatal hernia 
yes
hiatal hernia
no
hR*
(95% C.I.)
p-value
Number 331 74 257
Male 160 39 121 1
Female 171 35 136 0.76 (0.47; 1.21) 0.24
Age (yr) 
mean (S.D.)
51.1 (21.4) 59.9 (17.2) 48.6 (21.8) 1.03 (1.02; 1.04) <0.001
No Myotomy 296 63 233 1
Myotomy 35 11 24 1.6 (0.84; 3.03) 0.18
Pre LES-pressure
(mm Hg) 
median (range)
30.0 (5-207) 30.0 (5-100) 30.0 (7-207)
HR≤30 = 1
HR>30 = 1.09 (0.66; 1.78)
0.74
Post LES-pressure (mm Hg)
median (range)
15.0 (2-125) 13.0 (5-70) 15.0 (2-125)
HR≤15 = 1
HR>15 = 0.85 (0.50; 1.43)
0.53
Barrett absent
at time of HH
315 65 250 1
Barrett present 16 9 7 8.80 (4.32; 17.9)# <0.001
Table 2 Characteristics of patients with and without Hiatal Hernia and the corresponding Hazard Ratio‘s (HR)  
* HR estimated by univariate Cox regression analysis of the 70 cases with Hiatal Hernia during follow-up (the information of the date of Hiatal 
Hernia were missing in 4 cases). The log-likelihood p-value is reported.
 # HR of Barrett entered as a time-dependent covariate in the Cox regression analysis.
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der, therapy, LES-pressures, and hiatal hernia included (Table 3). Age was a significant factor 
involved in the development of hiatal hernia, but not in Barrett’s esophagus. In contrast, 
myotomy and a post-PD LESP < 15 mm Hg were significantly related to the development of 
Barrett’s esophagus, but not related to hiatal hernia. 
dISCuSSIOn
To our knowledge, only a limited number of patients have been described with the combina-
tion of achalasia and a Barrett’s esophagus 13-15. This includes a few patients who developed 
Barrett’s esophagus after pneumatic dilatation 14, 7 patients who were diagnosed with 
Barrett’s esophagus without being treated for their achalasia 14, 16, and 31 patients who had 
undergone surgical myotomy many years prior to the detection of Barrett’s esophagus 14, 
15. Six (16%) of these 39 patients were simultaneously or later diagnosed with esophageal 
adenocarcinoma. 
The incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus is 
considered to be approximately 0.5% per year of follow-up 17, 18 Therefore, the estimated 16% 
prevalence of esophageal adenocarcinoma in patients with achalasia and Barrett’s esopha-
gus as deducted from this figures above seems high. 
 This is the first study that systematically investigated the relationship between achalasia 
treated with pneumatic dilatation, Barrett’s esophagus and esophageal adenocarcinoma. We 
observed that 8.4% of 331 patients with achalasia developed a Barrett’s esophagus, in a single 
case prior to treatment, but mostly after dilatation treatment. Risk factors associated with the 
development of Barrett’s esophagus were the presence of a hiatal hernia, prior myotomy 
and a lower LES pressure. During follow-up, 2/28 (7%) patients with Barrett’s esophagus 
developed an esophageal adenocarcinoma. 
Myotomy was performed in 35 patients, in 19 patients this had occurred before referral, 
yet these 19 patients received renewed pneumatic dilatation for recurrent symptoms after 
Barrett
hR*  (95% C.I.)
p-value
hiatal hernia hR* 
(95% C.I.)
p-value
Age (yr)
mean (S.D.)
ns 1.03 (1.02; 1.05) <0.001
No Myotomy 1
Myotomy 3.49 (1.36; 8.93) 0.009 Ns
Post LES-pressure (mm Hg) ≤15 1
Post LES-pressure (mm Hg) >15 0.35 (0.13; 0.96) 0.04 Ns
HH / Barrett absent
at time of Barrett/ HH
1 1
HH / Barrett present
at time of Barrett/ HH
7.26 (3.19; 16.6)# <0.001 6.10 (2.87; 13.0)# <0.001
Table 3 Result of the multiple Cox regression analyses of the endpoints Barrett and Hiatal Hernia. The log-likelihood p-value is reported.
 # HR of covariate entered as a time-dependent covariate in the Cox regression analysis.
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surgery. Another 16 patients were treated with myotomy during FU, 6 of them received 
additional dilatation after surgery. Both treatment modalities have the same goal, namely 
disrupting the LES muscle fibers. A recent study could not show a superiority in success rate 
of myotomy 19 
The combination of achalasia and Barrett’s esophagus is considered to be rare as only 39 
cases of achalasia with Barrett’s esophagus have been reported in the literature mostly after 
myotomy 14, 15. Although Barrett’s esophagus and achalasia seem to be disorders at the op-
posing ends of a spectrum, our results show that there is an association between treatment 
of achalasia, leading to an insufficient LES, and the development of a Barrett’s segment. In 
our population, the prevalence of Barrett’s esophagus in achalasia patients after treatment 
was 7.4 %, with an annual incidence of newly development of Barrett’s esophagus of 1.0 % 
corresponding with a 1000 new cases per 100,000 subjects / year. 
These findings contrast with data on the prevalence and incidence of Barrett’s esophagus 
in the general population. Endoscopy and autopsy series have suggested a prevalence of 1 
% in Western populations 20. This prevalence may however be higher in selected populations. 
One study for instance reported a 25 % prevalence of Barrett’s esophagus in a population of 
male veterans 21. Estimates for the number of new cases per year vary between 10 and 48 per 
100,000 inhabitants 22, 23. We recently observed an annual incidence of 24.7 per 100,000 / year 
in a Dutch population of 386,000 subjects followed for 3.4 years 2.  In conclusion, our data 
suggest that patients treated for achalasia have a higher risk of developing Barrett’s esopha-
gus than the general population. As there is no age and sex comparable control population 
in our study of course there is surveillance bias. In the absence of such a population, we can 
only make an indirect comparison with other data. Klinkenberg-Knol et al observed that 20 
(12%) of 166 patients with severe reflux disease treated with omeprazole developed Barrett’s 
metaplasia during an average 6.5 years follow-up with annual endoscopy 24. This incidence 
is in the same order of magnitude as our observation of Barrett’s metaplasia in 7.3% of our 
achalasia patients during an average 8.9 years follow-up. 
Several hypotheses may explain the association between achalasia and Barrett’s esopha-
gus. The most obvious hypothesis is that efficient treatment leads to insufficiency of the LES 
predisposing to GERD and possibly to its complications25. This is supported by the association 
between a lower LES pressure and the development of Barrett’s esophagus in our cohort and 
also by our findings that esophagitis is very common during follow-up after PD 12. 
Although all achalasia patients were at each visits asked for esophageal complaints it can 
be difficult to discriminate symptoms related to the primary motility disorder and those 
related to the secondary reflux after treatment. Since most achalasia patients have persistent 
esophageal complaints we were unable to find a clear correlation between classical reflux 
symptoms and the development of Barrett’s esophagus after achalasia treatment.
Surprisingly in literature and also in our study a few achalasia patients appeared to have 
Barrett‘s esophagus already prior to baseline treatment. One hypothesis is that the develop-
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ment of Barrett’s esophagus had already occurred before achalasia started. Secondly it has 
recently been shown that transient LES relaxations (TLESR’s) accompanied by acid reflux may 
also occur in achalasia patients26. The combination of TLESR-induced acid reflux with impaired 
esophageal clearance may therefore be an explanation for the observed development of Bar-
rett’s esophagus in both treated and untreated achalasia patients. A last explanation could be 
that in (untreated) achalasia patients chronic food stasis and fermentation of retained food 
may cause chronic esophageal inflammation, predisposing to Barrett’s esophagus 16, 27 20, 28 
29, 30.
Apart from TLESR’s as a predisposing mechanism to reflux, the presence of a hiatal hernia 
is also an important etiologic factor in the development of GERD and Barrett’s esophagus. 
Various studies have reported a prevalence of hiatal hernia in 95% of patients with severe 
reflux and Barrett’s esophagus with a length of 3 cm or more and 74% in shorter Barrett’s 
esophagus 3, 31, 32. We found that 28% of patients with a hiatal hernia developed BE in contrast 
to only 3% of achalasia patients without a hiatal hernia and the presence of a hiatal hernia 
after treatment of achalasia revealed a hazard ratio of 8.04 to develop Barrett’s esophagus. 
We were surprised to find that 74 out of 331 (23%) achalasia patients had a hiatal hernia. 
Previous cross-sectional studies in achalasia have reported a prevalence varying between 1.4 
% and 2.3 % 33-35. Goldenberg et al described a higher prevalence, i.e., 14.1 % hiatal hernias 
in achalasia probably because radiographic examinations were reviewed 36. They found that 
8 of 10 radiographically demonstrated hiatal hernias had not been recorded in the clinical 
records proving underreporting probably because of the seemingly triviality of the diagno-
sis. The assessment of hiatal hernias poses some difficulties. Both barium swallow and upper 
GI endoscopy in particular have limited sensitivity in diagnosing small herniation 37, 38. High 
resolution manometry may be the most accurate instrument to diagnose these small hernia-
tions. We assessed the presence of a hernia during insertion of the scope and also used the 
retroflection view to grade the severity of the hernia and only diagnosed a hiatal hernia if the 
length was more than 2 cm. 
  Our results confirm that a hiatal hernia is not uncommon in achalasia patients and show 
that it is a significant risk factor for the development of Barrett’s esophagus after esophageal 
dilation (Figure 2).  
Barrett’s esophagus is a pre-malignant condition predisposing to esophageal adenocar-
cinoma. The esophageal cancer risk in patients with a Barrett’s esophagus differed between 
1/52 to 1/297 years of follow-up in different reports17. The incidence of adenocarcinoma in 
our achalasia patients with Barrett’s esophagus was 7.1% (2/28) during an average of 13.4 
years follow-up, which corresponds to previously mentioned annual risk of 0.5% 14. Review-
ing all the cases of achalasia combined with Barrett’s esophagus, Guo et al found that adeno-
carcinoma had occurred in 19 % of achalasia cases with Barrett’s esophagus, that developed a 
mean of 18 years after treatment for achalasia 14. The mean follow-up of the Barrett’s patients 
in our study was 13.4 years in total after achalasia diagnosis and 7.5 years after Barrett’s de-
Ivonne Leeuwenburgh BW 3.indd   66 24-02-12   11:47
67
Barrett’s esophagus
Ch
ap
te
r 5
velopment. With longer follow-up, the incidence of Barrett’s esophagus and adenocarcinoma 
in our cohort may further increase. The presence of Barrett’s esophagus could have alerted 
both patients and physicians, but we found no significant difference (p=0.4) in drop-out 
percentage between Barrett and non-Barrett patients. 
COnCLuSIOn
Patients with achalasia treated with pneumatic dilatation are at considerable risk for devel-
opment of Barrett’s esophagus. We observed the development of Barrett’s esophagus in 
28 (8.4%) of 331 achalasia patients before treatment and during long-term follow-up. This 
implicates that achalasia and Barrett’s are not mutually exclusive disorders. In contrast, 
achalasia and LES lowering therapy should be considered a risk factor for the development 
of Barrett’s mucosa. Hiatal hernia and lower esophageal sphincter pressures increases the risk 
to develop Barrett’s esophagus. During endoscopic and radiographic follow-up of achalasia 
patients, careful attention should be paid to the presence of hiatal hernia especially in combi-
nation with low LES pressures, since this combination strongly increases the risk for Barrett‘s 
esophagus and eventually adenocarcinoma of the esophagus.
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ABSTRACT
Introduction: Patients with longstanding achalasia have an increased risk of developing 
esophageal cancer. Surveillance is hampered by chronic stasis. We investigated whether 
aberrant expressions of tumor suppressor gene p53 and proliferation marker ki67 are early 
predictors for progression to malignancy.   
Methods: In 399 achalasia patients, 4% died of esophageal cancer despite surveillance. We 
performed a cohort study, using surveillance biopsies from 18 patients (11 carcinoma, 1 high 
grade dysplasia (HGD) and 6 low grade dysplasia (LGD)) and 10 controls (achalasia patients 
without cancer or dysplasia development). 164 biopsies were re-evaluated and studied for 
p53 and ki67 expression using immunohistochemistry. 
Results: 82% of patients with cancer/HGD showed p53 overexpression in surveillance biop-
sies at a mean of 6 (1 - 11) yrs prior to cancer development. In 67% of patients with LGD and 
only in 10% of the controls p53 overexpression was present. The proportion of samples with 
p53 overexpression increased with increasing grades of dysplasia. We found no difference for 
ki67 overexpression. 
Conclusions: p53 overexpression may identify achalasia patients at increased risk of de-
veloping esophageal carcinoma. Further study is needed to determine if patients with p53 
overexpression would benefit from intensive surveillance to detect esophageal neoplasia at 
a potential curable stage. 
KEy wORdS
Achalasia, esophageal cancer, surveillance, p53, immunohistochemistry
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InTROduCTIOn
Achalasia is a motor disorder of the esophagus characterized by aperistalsis of the distal 
esophagus in combination with absent or impaired relaxation of the lower esophageal 
sphincter (LES). This causes symptoms of esophageal obstruction. It is an uncommon disor-
der with an annual incidence of 1 per 100,000 in the Western world and an equal prevalence 
in men and women with a peak incidence around 60 years of age 1. Chronic food stasis (often 
present despite lower esophageal sphincter (LES) pressure lowering treatment) has been 
suggested to lead to chronic inflammation, epithelial hyperplasia, multifocal dysplasia and 
squamous cell carcinoma (SCC) 2-4. On the other hand LES-pressure lowering therapy by 
balloon dilatation or surgical myotomy may lead to chronic gastro-esophageal reflux, which 
in some cases is ultimately complicated by the development of Barrett esophagus (BE) and 
esophageal adenocarcinoma (AC) 5, 6, 7, 8.
Achalasia is considered to be a premalignant disorder. The reported risks for esophageal 
carcinoma vary widely between different studies. Several autopsy studies have reported an 
esophageal neoplasia prevalence of over 20% in achalasia patients at the time of death 9-11. 
Wychulis et al. conducted the largest cohort follow-up study in 1318 patients with achalasia 
followed for a mean of 17 years. This study revealed a seven-fold increased risk for esophageal 
cancer compared to the general population 12. Other follow-up studies reported esophageal 
cancer incidences varying from zero per 953 patient-years to 1 per 173 patient-years, which 
translates into relative risks varying from zero to 140 times increased compared to a sex- and 
age-adjusted population 13-15.  
Surveillance should aim at detection of neoplastic transformation at an early, curable 
stage, as well as at the identification of patients at the highest risk of developing neoplasia. 
These are in particular those patients, who have persistent severe inflammation or food stasis 
despite LES-pressure lowering therapies and those with BE. Unfortunately, surveillance in 
achalasia is difficult to perform due to stasis and mucosal adherence of food, which compro-
mise a careful inspection. Besides, most carcinomas develop in the middle and distal third 
of the esophagus and therefore, in contrast to Barrett’s esophagus, the whole length of the 
esophagus should be carefully inspected and sampled 16. Finally, histological evaluation of 
esophageal surveillance biopsy samples may be hampered by the persistent presence of 
chronic inflammation.
For these reasons, markers for the identification of patients at an increased risk of devel-
oping malignancy are needed. We therefore investigated whether expression of the tumor 
suppressor gene p53 and proliferation marker Ki67 are early predictors for progression to 
malignancy and are able to identify those patients with achalasia who are at highest risk 
of developing esophageal cancer. These markers were used earlier to predict malignant 
transformation in Barrett’s metaplasia 17, 18.
Ivonne Leeuwenburgh BW 3.indd   73 24-02-12   11:47
Chapter 6
74
MATERIAL And METhOdS
Patients
Since 1975 all patients with achalasia referred to our hospital have been treated and fol-
lowed according to a strict protocol. The total cohort consisted of 399 patients (male/female 
198/201), who have been followed for a mean of 8.1 years (0 – 25.9) after diagnosis. The 
diagnosis and treatment protocol did not change over time and patients were taken care 
of by a selected number of physicians over the complete period of follow-up of the cohort. 
All patients were first treated with repeated pneumatic dilatation on three consecutive days 
using Rigiflex balloons (Boston Scientic, Natick, MA, USA) with increasing diameter (30/35/40 
mm). Recurrent symptoms were treated by repeat dilation. Patients with an early (within 3 
months) or repeated recurrence (after 3-4 dilation sessions) of symptoms were referred for 
Heller myotomy in combination with a Dor fundoplication. 
Surveillance endoscopies were performed at least every three years. During surveillance a 
careful inspection of the esophagus was performed and random biopsy samples were taken 
from the distal part of the esophagus, 1-2 cm above the presumed LES. Suspicious areas were 
separately sampled. If food stasis compromised clear vision, patients were asked to return 
after a 3-day liquid diet. Patients who refused surveillance endoscopies or were considered 
too old to undergo surveillance were followed by phone calls at regular intervals.
Twelve achalasia patients (M/F 7/5) who developed esophageal cancer or high grade 
dysplasia (HGD) were included in the current study. In addition ten achalasia patients with 
comparable duration of achalasia, gender and age but without esophageal cancer served as 
controls. Six patients, who developed low-grade dysplasia (LGD, 3 in BE) during follow-up, 
were also included in this study.
Histology and immunohistochemistry:
From the patients who developed esophageal carcinoma or dysplasia all available samples 
and from the control patients the five most recent biopsy samples were re-evaluated for the 
presence of Barrett’s esophagus, dysplastic changes (LGD or HGD) and carcinoma (AC or SCC) 
by an expert GI-pathologist (H. van Dekken) who was blinded for the clinical information. The 
available paraffin blocks of these samples were retrieved from the archive and studied for p53 
and ki67 expression using immunohistochemistry.
Four µm tissue sections of the formalin-fixed, paraffin wax-embedded samples were sliced 
and mounted on adhesive slides, dried and deparaffinized with xylene and rehydration 
through graded ethanol. Antigen retrieval was performed by boiling these samples for 15 
minutes in 10 mM monocitric acid buffer (pH 6.0) for ki67 staining and in 10mM Tris/EDTA 
buffer (pH 9.0) for p53 staining. Prior to immune staining, endogenous peroxidase activity 
was blocked by incubating the slides in a 0.5 % solution of H2O2 in phosphate-buffered citric 
acid for 15 minutes at room temperature. Samples were 3 times washed with TRIS-buffered 
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saline (TBS) with a pH of 7.4. The samples were incubated in TBS buffer containing 10% rabbit 
non-immune serum (DAKO, Glostrup, Denmark) and 10% normal human plasma (and 5% 
BSA for p53 staining) for 20 minutes. Sections were incubated with the primary antibody 
anti-human ki67 antigen (clone MIB-1, DAKO) in a 1:100 dilution or p53 antigen (clone DO-7, 
DAKO) in a 1:100 dilution for 14 hours at 4ºC. Subsequently, biotin-labelled rabbit-anti-mouse 
antibody (DAKO) was used as second antibody followed by the addition of a streptavidin-
horseradish peroxidase complex (DAKO). To detect ki67 and p53, 3-amino-9-ethylcarbazole 
was used as substrate. Two independent researchers who were blinded to the clinical data 
counted at least 300 nuclei in every sample. Only longitudinally sectioned squamous and 
Barrett’s epithelium was evaluated. Cells were counted as positive when moderate to intense 
red nuclear staining was found. An isotype and a negative control staining were performed. 
Samples were considered p53 and ki67 positive if more than 15% of nuclei were stained (Fig 
1). When the counts of both researchers on a specific sample differed more than 10%, both 
researchers counted the sample again. When there was still at least a 10% difference a third 
researcher counted the sample for a final classification (negative / positive). 
Statistics
Statistical analyses were conducted using SPSS software. (SPSS version 13.0, Chicago, IL, USA). 
Chi-square tests and t-tests were used to analyse the results of ki67 and p53 expression. The 
hazard ratio to develop carcinoma or high-grade dysplasia was calculated using Cox regres-
sion analysis, with and without adjustment for histology, using age as the time-axis and p53 
status as a time dependent variable. The time course of p53 expression of the carcinoma 
patients in time was visualised using cubic spline functions in S-plus 6.0 software (Insightful 
Inc, Seattle WA).
figure 1: examples of ki67 (A) and p53(B) overexpression in esophageal biopsy samples of patients with achalasia. 
A B
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RESuLTS
Patients
From 12 cancer cases (eight SCC, three AC and one HGD), 65 follow-up biopsy samples, 
obtained prior to the development of malignancy, were available. The mean age of these 
patients at achalasia diagnosis was 62.5 years (range 33 - 80) and they were followed-up 
for a mean of 22 years (range 9 - 33) after the onset of achalasia symptoms. One patient, 
who developed HGD during follow-up and underwent esophageal resection, was included 
in this group. In addition six patients (mean age at diagnosis 50 years (range 28 - 62) and 
followed-up for a mean of 20 years (range 5 - 44) who developed (LGD) during follow-up) 
were also selected and included. Ten patients with a mean age of 46 years (range 17-75) and 
a mean follow-up of 21 years (range 14 - 28) after start of achalasia symptoms and at least five 
available samples served as controls. Patient characteristics are listed in Table 1.
Histology
One hundred sixty-four samples from 28 patients were re-evaluated. All three patients with 
AC who had undergone an average of 5 (range 2 - 8) endoscopies with biopsy sampling 
during follow-up displayed BE in biopsies taken prior to cancer development, whereas only 
one patient showed LGD and HGD prior to cancer development. 
From eight patients who had undergone an average of 5.4 (range 3 - 10) endoscopies with 
biopsy sampling during follow-up, who developed SCC, only three patients were diagnosed 
with LGD or HGD in the prior biopsies. One patient already displayed LGD, one also HGD and 
in one patient some of previous biopsies showed BE and/or LGD.  
In the patient with HGD, this dysplasia developed in previous noticed BE with already LGD 
in two earlier samples.
Esophageal cancer/high 
grade dysplasia patients
n=12
Low grade dysplasia patients
n=6
Control patients
n=10
Squamous cell ca 8
Adenocarcinoma 3
Low grade dysplasia 6
High grade dysplasia 1
Barrett’s metaplasia 4 3 0
Male/female 7/5 4/2 6/4
Age of diagnosis 63 (33-80) 50 (28-62) 46 (17-75)
Duration of symptoms till carc/
dysplasia/end fu
23 (9-33) Dysplasia: 11 (4-23)
End FU: 20 (5-44)
21 (14-28)
Age of carcinoma/end FU 74 (38-88) 65 (53-76) 63 (30-84)
Table 1: Patient characteristics
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Six LGD patients had undergone an average of 6.5 (range 3 - 10 per patient) endoscopies 
with biopsy sampling during follow-up. Three of them also had BE in the biopsy samples prior 
to and together with dysplasia development. In three patients LGD was present in some of 
the consecutive samples, but this was no longer found in samples taken at a later time point 
during follow-up. The other three patients showed LGD in the more recent samples, obtained 
at the end of follow-up. 
Ten controls had undergone biopsy sampling during their follow-up with an average 5.6 
(range 5 - 7 per patient) endoscopies. Dysplasia and metaplasia were not present in any of 
these samples upon blinded revision. 
Ki67 expression
Ki 67 expression was assessed in 135 samples from 28 achalasia patients (Fig 2). Eighteen 
paraffin blocks were missing in the archive and 14 slides were empty or not assessable due to 
background staining. Ki67 expression was positive in 45/51 (88.2%) control patient samples, 
26/30 (86.7%) samples from dysplasia patients and 47/54 (87.0%) esophageal cancer or HGD 
patient samples. Chi-square testing showed no statistically significant differences between 
these groups (p=0.97).  In addition the proportions of positive nuclei were not significantly 
different between the three groups (87% in cancer and HGD cases, 86.7% in LGD cases and 
88.2% in controls); (p=0.38 cancer compared to controls; p=0.69 LGD compared to controls).
ki67 expresion
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figure 2: Number of ki 67 positive nuclei in esophageal biopsies without dysplasia (ND), with low-grade dysplasia (LGD), with high-grade 
dysplasia (HGD) and with carcinoma. 
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p53 expression
p53 expression was determined in 133 samples from all 28 achalasia patients (Fig 3). In the 
control group, 2/48 (4%) biopsy samples (both from one patient) showed p53 overexpres-
sion. These biopsies had been taken during the last follow-up endoscopy in this patient. In 
patients who developed LGD 11/37 (29.7%) biopsy samples were positive (in 67% of patients). 
In patients esophageal cancer or HGD, 25/48 (52.1%) biopsy samples were positive (in 82% 
of patients). 
The first positive sample had been obtained at a mean of 6 years (range 1- 11 yrs) prior 
to cancer development (Fig 4). The proportion of biopsy samples with p53 overexpression 
increased with increasing grades of dysplasia (19/103 (18%) in no dysplasia, 8/16 (50%) in 
LGD, 3/3 (100%) in HGD and 8/10 (80%) in AC and SSC (p<0.001).
Of all 37 p53 positive samples, 18 (49 %) also showed dysplasia or carcinoma. 
Correcting for the number of samples per patient and age this indicates a hazard ratio 
(HR) of 8.0 (95% confidence interval 1.6 - 41) for p53 positive patients to develop carcinoma 
in comparison to p53 negative patients (p=0.013). The HR for patients with LGD to develop 
carcinoma compared to patients without LGD was 0.98 (95% confidence interval 0.3 - 3.5) 
(p=0.97) 
The gradual increase over time in p53 overexpression is shown in Figure 5. From this, it 
can be seen that p53 overexpression increased at time points closer to the development of 
esophageal cancer. Moreover, p53 overexpression was already present at a mean of 6 years 
prior to cancer development at a time when there were no endoscopical signs of progression 
towards neoplasia. 
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figure 3: Number of p53 positive nuclei in esophageal biopsies without dysplasia (ND), with low-grade dysplasia (LGD), with high-grade 
dysplasia (HGD) and with carcinoma.
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figure 4: Fraction of patients with a positive p53 sample in the years prior to HGD or cancer development.  
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figure 5: Overexpression of p53 in esophageal biopsy samples from achalasia patients taken some years prior to HGD or cancer development. 
At t=0 (presence of HGD or esophageal cancer) the fraction of p53 overexpression is 83%.
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dISCuSSIOn
Patients with achalasia have a significantly increased risk of developing of esophageal cancer, 
both squamous cell carcinoma and adenocarcinoma. This is thought to be related to chronic 
food stasis and impaired esophageal clearance, which often persists after dilation treatment. 
In this study we therefore focused on both tumour types. Achalasia patients with esophageal 
cancer often have an even more dismal prognosis than other esophageal cancer patients. This 
is at least partly due to the fact that these patients are used to symptoms of impaired food 
passage and often report worsening of their symptoms at a stage of advanced malignancy 19. 
This warrants the consideration for surveillance endoscopies in these patients. However the 
benefit of surveillance endoscopies in achalasia is disputed because a diagnosis of neoplasia 
in achalasia at an early and therefore presumably curable stage is often difficult. The findings 
of this longitudinal analysis show that easily to apply biomarkers such as p53 can be used for 
the detection of patients at an increased risk of neoplastic progression. 
Almost all patients with achalasia, with or without future development of HGD or esopha-
geal cancer, showed overexpression of ki67 in biopsies taken from the esophagus at time 
points before macroscopically or microscopically presence of neoplastic changes. Conse-
quently, this marker was found to be not discriminative between patients at risk or those not 
at risk for the development of esophageal cancer in achalasia. 
The human ki67 protein is present during all active phases of the cell cycle (G1, S, G2, M), 
but is absent in resting cells (G0). Although some of its features have been characterized, 
such as phosphorylation and transport to the cell nucleus for expression to become evident, 
the exact function of the ki67 protein is still largely unknown. Expression of the ki67 pro-
tein is strictly associated with cell proliferation. The fraction of ki67 positive cells has been 
demonstrated to correlate with the clinical course of the neoplastic disorder 20. Our results 
confirm the previously reported presence of hyperproliferation in the esophageal mucosa of 
achalasia patients 3. 
It can be assumed that this hyperproliferation is one of the risk factors for development 
of LGD, HGD and esophageal cancer in these patients with achalasia. The hyperproliferation 
is likely caused by the commonly observed food stasis and fermentation in the distal part of 
the esophagus in these patients. To test this hypothesis, biopsies taken at higher levels in 
the esophagus should be examined assuming that distally more stasis and therefore, more 
hyperproliferation is present. In the current study, surveillance biopsies were always taken 
1- 2 cm above the GE-junction.  Another problem with ki67 expression is the presence of 
inflammation in esophageal samples of achalasia patients. Inflammation causes to extend 
ki67 expression to upper layers of the epithelium. This can be another explanation for the 
high number of ki67 positive samples.
Overexpression of p53 was more frequently observed in achalasia patients who developed 
esophageal cancer at a later time point. Of the 12 investigated esophageal cancer or HGD 
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patients, only 5 displayed histological evidence of dysplasia prior to cancer/HGD develop-
ment, whereas 10 patients already showed p53 overexpression at an earlier stage (Fig 5). 
Most importantly, this overexpression was already noted at a mean of 6 years prior to cancer 
development and was a significant predictor for progression towards neoplasia (HR 8.0 (95% 
confidence interval 1.6 - 41). The hazard ratio was corrected for the fact that the number of 
samples differed between patients and that the patients in the control group were younger. 
It is important to stress, that the presence of LGD did not affect this ratio. 
The p53 tumour suppressor gene is located on the 17p13 chromosome and is involved 
in controlling cell proliferation. Normally, cells contain low levels of wild-type p53 which 
regulates two common responses to oncogenic stress, i.e. cell cycle arrest/DNA repair and 
apoptosis. In cells that are early in the G1-phase, p53 triggers a checkpoint blocking further 
progression through the cell cycle, allowing the damaged DNA to be repaired before the cell 
enters the S-phase 21. If the DNA damage cannot be repaired, p53 induces apoptosis 22. This 
suggests that failure of p53 to respond to DNA damage will increase the susceptibility to 
oncogenic changes.
Mutated p53 is dominantly negative and it overwhelms the wild-type protein and pre-
vents it from functioning 23. These p53 mutations are associated with an increased half-life 
of the p53 protein, resulting in the accumulation in the cell nucleus to levels that can be 
detected by immunohistochemistry 24. In contrast, wild-type p53 has a short half-life and, 
as a consequence, these proteins do not accumulate and are mostly below the threshold of 
being detected by immunohistochemistry 25Approximately 90% of p53 mutations are point 
mutations 26. 
Although immunohistochemistry for detecting mutated p53 is cheap, quick and easy 
to apply compared with other techniques, there are some additional limitations that are 
important to consider. The p53 antibodies that are commonly used do not only stain the 
mutant p53 mutation but probably also the wild-type 25. A second limitation of p53-based 
immunohistochemistry is that mutations for this tumour suppressor gene may exist without 
protein overexpression, and therefore will not be detected by immunohistochemistry 25-27. As 
with ki67 expression, presence of inflammation can influence p53 evaluation. It is important 
to stress that only intense red cells were considered p53 positive.
Nevertheless these limitations, our results suggest that p53 is an early marker of neoplastic 
progression in achalasia. 
In the current study, we controlled for duration of disease; however, the three patient 
groups differed with respect to age, with esophageal cancer patients being the oldest at 
the time of achalasia development and the control patients being the youngest. The most 
likely explanation for this is that we selected on outcome (cancer, LGD, no dysplasia), which is 
related to age. In the reported hazard ratio of 8.0 a correction for age was made.   
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COnCLuSIOn
This longitudinal cohort study suggests that p53 but not ki67 can well be used to identify 
achalasia patients at the highest risk of developing malignancy. Consequently, achalasia 
patients with p53 overexpression may benefit from a more intensive surveillance interval and 
possibly the use of newer imaging techniques such as high resolution endoscopy or chrome 
endoscopy to detect neoplastic changes at an earlier and therefore potentially curable stage. 
This should however be studied in a prospective follow-up study.
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ABSTRACT
Background: Pneumatic balloon dilatation (PD) is a regular treatment modality for achalasia. 
The reported success rates of PD vary. Recurrent symptoms often require repeated PD or 
surgery. 
Objective: To identify predicting factors for symptom recurrence requiring repeated treat-
ment. 
Methods: Between 1974 and 2006, 336 patients were treated with PD and included in this 
longitudinal cohort study. The median follow-up was 129 months (range 1-378). Recurrence 
of achalasia was defined as symptom recurrence in combination with increased lower 
esophageal sphincter (LES) pressure on manometry, requiring repeated treatment. Patient 
characteristics, results of timed barium esophagram and manometry, as well as baseline PD 
characteristics were evaluated as predictors for disease recurrence with Kaplan-Meier curves 
and Cox regression analysis. 
Results: 111 patients suffered from symptom recurrence requiring repeated treatment. 
Symptoms recurred after a mean follow-up of 51 months (range 1-348). High recurrence per-
centages were found in patients younger than 21 years in whom the 5-year and 10-year risk 
of recurrence were 64% and 72%, respectively. These risks were respectively 28% and 36% 
in patients with classic achalasia, respectively 48% and 60% in patients without complete 
obliteration of the balloon’s waist during PD and respectively 25% and 33% in patients with 
a LES-pressure of > 10 mmHg at 3 months post-dilatation. These four predictors remained 
statistically significant in a multivariable Cox analysis.
Conclusion: Although PD is an effective primary treatment in patients with primary achala-
sia, patients are at risk for recurrent disease, with this risk increasing during long-term follow-
up. Young age at presentation, classic achalasia, high LES pressure 3 months after PD, and 
incomplete obliteration of the balloon’s waist during PD are the most important predicting 
factors for the need of repeated treatment during follow-up. Patients who meet one or more 
of these characteristics may be earlier considered for alternative treatment, such as surgery.
KEywORdS: 
achalasia, pneumatic balloon dilation, predictor, recurrence
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STudy hIGhLIGhTS
1 What is already known about this subject: 
Several studies have reported success rates of PD between 35% and 85%.
The previous identified risk factors for symptom recurrence after PD were mainly young 
age (< 40 years), a post-treatment LES pressure above 10 mmHg and a short period of symp-
toms prior of treatment.
Laparoscopic myotomy combined with an antireflux procedure provides better symptom 
relief than all endoscopic and other surgical approaches, with a low complication rate.
2 What are the new findings: 
After treatment with PD we found a 5-year risk of recurrence of 28%.
Given the long follow-up period in our study, we were able to show that the rate of recur-
rence does increase over time.
Young age at presentation, a manometric pattern of classic achalasia, high LES pressure 3 
months after PD, and incomplete obliteration of the balloon’s waist during PD are the most 
important predicting factors for the need of repeated treatment during follow-up.
3 How might it impact on clinical practice in the foreseeable future?
This implies that a stricter follow-up can be given to patients with the above mentioned 
predicting factors, as the chance of recurrence is significantly higher in this subgroup. Using 
a stricter follow-up, recurrence (defined as symptom recurrence in combination with objec-
tive parameters such as a significant increase in LES pressure) can be diagnosed at an earlier 
stage.
Patients who meet one or more of these characteristics may be earlier considered for 
alternative treatment, such as surgery.
InTROduCTIOn
Achalasia is a rare condition, with an estimated annual incidence of 1 per 100,000, character-
ized by a functional obstruction of the esophagus caused by failed relaxation of the lower 
esophageal sphincter (LES) in combination with absent peristalsis of the distal esophagus1. 
The etiology of achalasia is still unknown. The disease is characterized by a loss of inhibitory 
nitrinergic neurons in the esophageal myenteric plexus. Proposed causes include genetic 
inheritance, neuronal degeneration, viral infection, and autoimmune disease 2. The character-
istic symptoms of patients with achalasia are dysphagia for solids and liquids, regurgitation 
of undigested food or saliva, respiratory complaints (nocturnal cough, aspiration), retroster-
nal pain and weight loss. Therapeutic options aim to improve esophageal emptying by 
decreasing LES pressure. There are several treatment options, either endoscopic (botulinum 
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toxin injection and pneumatic balloon dilatation) or surgical3. Most gastroenterologists pre-
fer pneumatic balloon dilatation as first line therapy. Nevertheless, the reported success rates 
of pneumatic dilatation vary widely, ranging in previous studies from 35 to 85 percent within 
several years of follow-up 4-11. These marked differences may be partly explained by differ-
ences in the length of follow-up. Recurrence of symptoms often requires repeated pneumatic 
dilatation or further treatment with surgery. The major determinants for pneumatic dilata-
tion therapy failure are insufficiently known: such knowledge would be clinically relevant as 
it may aid in targeted surveillance and early intervention in high-risk groups. Several studies 
therefore tried to identify predicting factors of clinical outcome following pneumatic balloon 
dilatation. Some did not find any specific predictor 10. Other studies found that advanced 
age, female gender, a long history of symptoms prior to diagnosis, high pre-therapeutic LES 
pressure, a post-dilatation LES pressure of < 10 mmHg, limited contrast retention on barium 
esophagram post dilatation, and a higher number of repeated baseline pneumatic dilata-
tions were associated with a favourable treatment outcome 5, 6, 8, 11-15. These studies were 
often performed with relatively small groups of patients. Aim of this study therefore was to 
identify predicting factors for symptom recurrence requiring repeated pneumatic dilatation 
in a large cohort of patients with primary achalasia. 
PATIEnTS And METhOdS
Patients
From 1974 to 2006, 433 patients (214/219 M/F), mean age 51.1 ± 21.6 years (range 4-92) were 
diagnosed with primary achalasia in our centre. Their data were prospectively included in 
a database, and they were treated and followed according to a strict patient management, 
treatment and follow-up protocol, which remained unchanged throughout the study period.
Diagnosis
The diagnosis of achalasia was based on results from upper GI endoscopy, manometry and 
timed barium esophagram.
Endoscopy  
Upper GI endoscopy using a fiber- or video-endoscope (Olympus Europe, Hamburg, Ger-
many) was performed to rule out secondary achalasia. 
Esophageal manometry 
Esophageal manometry was performed using a low compliance, pneumohydraulic water 
infusion system (Medical Measure Systems (MMS), Enschede, the Netherlands) and a four-
channel silicone catheter (MMS, Enschede, the Netherlands). From May 2005 onwards we 
used an eight-channel water-perfused manometry assembly with an incorporated 6 cm long 
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reversed-perfused sleeve sensor (Dentsleeve International Ltd, Mississauga, ON, Canada). 
The recording sites were connected to an eight-channel polygraph (MMS). The four channel 
catheter was introduced with all four recording sites in the stomach and then manually pulled 
back per centimeter with a wet swallow of 5cc water at each centimeter. The eight-channel 
catheter was introduced in the stomach and then manually pulled back till the sleeve was 
positioned at the level of the LES. Mean resting LES pressure was calculated as the mean 
end-expiratory LES pressure during ten wet swallows. LES relaxations were considered to 
be absent if no change was recorded after swallowing and complete if swallow-induced LES 
pressure returned to the basic intra-gastric level. A pressure fall above basic gastric level was 
considered as partial relaxation. Peristaltic wave amplitudes were also calculated as mean 
wave amplitudes during ten wet swallows. A-peristalsis was diagnosed if all contractions 
after swallowing were simultaneous. We differentiated two patterns of aperistalsis. Classic 
achalasia was defined with the presence of non-transmitted or simultaneous contractions 
with a low amplitude. Vigorous achalasia was diagnosed if there were simultaneous contrac-
tions with an amplitude of more than 37 mm Hg.
Timed barium esophagram 
Timed barium swallow was performed in standing position after an overnight fast. The patient 
was asked to drink 200 cc barium solution (or as much as tolerated without regurgitation or 
aspiration) and recordings of the esophagus were performed at 0, 1 and 10 minutes after the 
last barium swallow. The appearance of a so-called “bird’s beak” was recorded, and the height 
and maximal width of the barium column were measured at 1 and 10 minutes. 
Pneumatic dilatation
From 1974 till 1976, homemade pneumodilatators were used. Since then, dilatation balloons 
became commercially available, and PD procedures were performed using a Rigiflex balloon 
(Boston Scientific, Natick, MA, USA).
Baseline pneumatic dilatation was performed on three consecutive days with balloons 
of either the same or incremental (30, 35, and 40 mm) diameter. We initially used a 40 mm 
balloon for all three consecutive dilatations. Under the assumption of lower perforation risk, 
we later adapted this protocol to a graduated approach using balloons with incremental 
diameters of 30, 35, and 40 mm respectively, inflated like before on successive days. In case 
of recurrence, we performed a new series of dilatations on 3 consecutive days, again with 
the same protocol as used for initial treatment. After changing our protocol to the gradu-
ated approach, all patients with a recurrence were treated with this protocol, irrespective 
of the earlier balloon diameter protocol used.  Under conscious sedation the balloon was 
positioned fluoroscopically at the gastro-esophageal junction and inflated to a pressure of 
300 mm Hg for 1 minute. Till mid-2001 patients were hospitalized for 4-5 days, but later we 
switched to an outpatient procedure. 
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We only performed a post-procedural esophagram using water-soluble contrast on suspi-
cion of a perforation after pneumatic dilatation. Dilatation of the esophagus to any extent on 
a timed barium esophagram was no exclusion criterion for PD.
Post dilatation follow-up
Following pneumatic dilatation, all patients had a strict schedule of follow-up at 3, 12, 24 
months and then every 2 years. Surveillance included upper G-I endoscopy, manometry 
and timed barium esophagram. After 8 years of follow-up surveillance included upper G-I 
endoscopy, further examination was performed on indication. This schedule was consistently 
followed for all patients from 1974.
Recurrence of achalasia was defined as relapse of symptoms (in particular dysphagia, re-
gurgitation and weight loss) in combination with an increased LES pressure on manometry in 
comparison with the prior LES pressure, requiring further treatment. We did not use a specific 
quantified symptom instrument to define symptom recurrence. Primary failure of treatment 
was defined as persistence or recurrence of symptoms in the first 3 months after pneumatic 
dilatation.
Evaluation of predictors for disease recurrence
Patient characteristics (age at presentation, gender), the results of timed barium esopha-
gram, manometry before treatment,  pneumatic dilatation balloon characteristics (stable vs. 
incremental diameter, and complete vs. incomplete obliteration of the balloon’s waist during 
dilation), as well as the results of repeated manometry 3 months post-treatment were evalu-
ated as predictors for disease recurrence. 
Time to recurrence was calculated from first pneumatic dilatation. Kaplan-Meier curves 
were constructed to estimate the 5 and 10-year cumulative incidence of recurrence. Cox 
proportional hazards regression was used to estimate univariable and multivariable hazard 
ratios. Associations between continuous predictors and recurrence were analysed with re-
stricted cubic spline functions on the log hazard scale 16. These splines allow for a flexible fit 
the non-linear effects of predictors with relatively few degrees of freedom (df ). The predictive 
strength of each predictor in the multivariable model was indicated by a chi-square statistic, 
based on the difference in –2 log likelihood of a model with and without the predictor 17. 
Statistical analysis was performed using SPSS (version 12.0, SPSS Inc, Chicago, IL, USA), and R 
software (version 2.5.1, R Foundation for Statistical Computing, Vienna, Austria).
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RESuLTS
Patients characteristics
From 1974 to 2006, 433 patients were diagnosed with achalasia based on the above-men-
tioned criteria. Thirty-seven of them did not undergo pneumatic dilatation for various reasons 
including failure of prior treatment elsewhere, or direct preference for cardiomyotomy. The 
remaining 396 patients were treated with pneumatic dilatation. Sixty (15.2%) of them were 
excluded from analysis since they had undergone previous endoscopic or surgical treatment 
elsewhere. The remaining 336 patients were included for analysis, including 161 men and 175 
women, with a mean age at initial presentation of 50 years (range 4 - 92 yrs). In 288 of 336 
patients a manometric subclassification of achalasia could be made. There were 222 (77%) 
patients with classic achalasia and 66 (23%) patients with vigorous achalasia. The median 
follow-up of all patients was 129 months (range 1-378).  During follow up 94 (28%) patients 
died and 74 (22%) patients were lost to follow up. Two-hundred and twelve patients (63%) 
were at baseline treated with the fixed 40 mm balloon protocol, 63 (19%) were treated with 
the incremental balloon protocol, and the remainder 61 patients were treated with another 
dilatation protocol, fixed 30 mm balloon, fixed 35 mm balloon or unknown protocol.
Complications
Among a total of 985 pneumatic dilatations performed in 336 patients, 40 (4.1%) procedures 
were associated with one more complications. The complications are summarized in Table 1. 
In 13 (1.3%) of the 985 pneumatic dilatations, an oesophageal perforation occurred. Two of 
these patients required surgery; one patient underwent primary repair of the esophagus and 
one patient esophageal resection. An esophageal stent was temporary placed in one patient. 
The other 10 patients underwent conservative treatment with antibiotics and no oral feed-
ing. There was no mortality and all patients had a good clinical outcome and were discharged 
17±7.9 days after the perforation. Perforation occurred in 5 (2.4%) of the 212 patients who 
were repeatedly treated with a 40 mm balloon, versus 1 (1.6%) of the 63 patients who were 
treated with incremental size balloons. 
Complication Nr of procedures (n=985) Percentage (%)*
None 945 95.9
Post-procedural pain 31 3.1
Fever 16 1.6
Perforation 13 1.3
Aspiration 3 0.3
Bleeding 2 0.2
Table 1 Complications related to PD (* proportions do not add up to 100% as some patients had more than one complication, such as the 
combination of post-procedural pain, fever, and perforation)
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Six perforations occurred in patients who were treated with a fixed dilatation protocol with 
a 35 mm balloon. One perforation occurred in a patient with an unknown dilatation proto-
col. Perforations occurred in 5 / 161 (3.1%) males versus 8/ 175 (4.6%) females (p<0.001). 
They were also more common in patients with complete obliteration of the balloon waist 
(complete vs. incomplete 5.1 vs. 1.8%, p<0.001). There were no associations between perfora-
tion rates and age, LES pressure on manometry before pneumatic dilatation, or duration of 
achalasia symptoms before diagnosis.   
Overall outcome
During follow-up, 111 of the 336 patients developed recurrence of achalasia requiring 
further treatment. These first recurrences occurred at a mean interval of 51 months (range 
1-348 months) after baseline treatment (Figure 1). In 12 patients the symptoms persisted or 
recurred within the first 3 months after pneumatic dilatation 
Time (months)
4003002001000
P
ro
ba
bi
lit
y 
of
 r
ec
ur
re
nc
e
1,0
0,8
0,6
0,4
0,2
0,0
figure 1 Kaplan-Meier curve for the probability of symptom recurrence after successful primary pneumatic balloon dilatation for achalasia
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Recurrences were treated with renewed pneumatic dilatation in 88 (79%) of the 111 pa-
tients, the remainder received other treatment modalities, in particular cardiomyotomy (9%) 
and botulinum toxin injection (3.6%). The five-year risk of recurrence was 28%; the ten-year 
risk of recurrence was 34% (Table 2). 
Forty-six of the 88 patients who had been treated with repeated pneumatic dilatation for 
disease recurrence, developed second recurrence of achalasia at a mean interval of 70 months 
(range 13-372 months) after renewed pneumatic dilatation. Second recurrences were treated 
with renewed pneumatic dilatation in 34 (74%) of the 46 patients. Fifteen of those 34 patients 
developed a third recurrence of achalasia at a mean interval of 109 months (range 22-242 
months) after renewed pneumatic dilatation and were then treated with renewed pneumatic 
dilatation in 9 (60%) of the 15 patients.  
Predictors of outcome: univariate analysis
The risk of recurrence was significantly higher in younger patients, those with classic acha-
lasia, those with incomplete obliteration of the balloon’s waist during pneumatic dilatation, 
and patients with an LES pressure > 10 mmHg at 3 months after treatment (Table 2). The other 
factors tested, including gender and balloon diameter used during pneumatic dilatation, did 
not influence the risk of recurrence. Furthermore, the presence or absence of esophageal 
dilation on a timed barium esophagram at presentation, as well as LES pressure before treat-
ment did not significantly differ between patients with or without recurrence of achalasia 
during follow-up.
Table 2 shows that in 10 patients, a presumptive diagnosis of achalasia was made despite 
low LES pressures on manometry. In view of the clinical picture with typical symptoms, a 
fully compatible barium esophagram, and a non-relaxing LES with stasis during endoscopy 
without signs of obstructing lesions, the presumptive diagnosis of achalasia was made and 
patients were treated with balloon dilatation. The response to this therapy in all 10 patients 
with improvement of both symptoms and barium esophagram supported the diagnosis of 
achalasia and suggest that the low LES pressures were due to misreading in the manometry. 
These patients were therefore included in our analysis, separate analysis with exclusion of 
these 10 patients did not lead to any major changes in results.
Multivariable analysis
Multivariable analysis showed that age at presentation under 50 years (with increased risk 
in patients with a younger age), classic achalasia, incomplete obliteration of the balloon’s 
waist during pneumatic dilatation, and LES pressure at 3 months after treatment over 12 mm 
Hg were significant independent factors to predict the development of later recurrence (all 
p-values < 0.001). No significant interaction effects were found between these risk factors (all 
p>0.05), and no simple combinations of characteristics of high risk patients could be found.
Ivonne Leeuwenburgh BW 3.indd   95 24-02-12   11:47
Chapter 7
96
Relative hazard threshold in LES-pressure and age
We examined the relation between LES pressure measured at 3 months after pneumatic dila-
tation and the risk of recurrence in further detail (Figure 2). The higher the LES-pressure post 
dilatation, the greater the relative hazard ratio for recurrence. We found a threshold value of 
12 mm Hg. Above this pressure the risk of recurrence increased more or less linearly. Younger 
age increased the relative hazard ratio for recurrence (Figure 3). We found a threshold value 
of 50 years, below which the risk of recurrence increased linearly.
Characteristic N Recurrence 
(n)
5 yr risk of 
recurrence 
(SE)
10 yr risk of 
recurrence 
(SE)
Hazard ratio 
(95% CI)
P-value
Sex
Male
Female
161
175
52
59
0.27 ± 0.04
0.29 ± 0.04
0.33 ± 0.04
0.37 ± 0.04
1.0
1.02 (0.7-1.5)
0.93
Age (years) at onset
< 21
21-40
40-50 
> 50
31
91
46
168
23
42
11
35
0.64 ± 0.9
0.31 ± 0.5
0.17 ± 0.6
0.21 ± 0.3
0.72 ± 0.09
0.38 ± 0.06
0.33 ± 0.10
0.24 ± 0.04
1.0
0.4 (0.3-0.7)
0.3 (0.1-0.5)
0.2 (0.1-0.4)
< 0.001
Type of achalasia
Classic 
Vigorous
222/288
66/288
79
15
0.28 ± 0.03
0.18 ± 0.05
0.36 ± 0.04
0.21 ± 0.06
1.8 (1.0-3.2)
1.0
0.032
Timed barium esophagram
Esophagus dilation yes
Esophagus dilation no
275/326
51/326
87
21
0.27 ± 0.03
0.31 ± 0.07
0.33 ± 0.03
0.37 ± 0.07
1.0
1.3 (0.8-2.0)
0.36
Manometry before treatment
LES p ≤ 10 mm Hg
LES p > 10 mm Hg
10/282
272/282
3
88
0.29 ± 0.18
0.25 ± 0.28
0.29 ± 0.18
0.32 ± 0.03
1.0
0.9 (0.3-3.0)
0.91
Obliteration balloon’s waist
Yes
No 
217/327
110/327
45
62
0.16 ± 0.03
0.48 ± 0.05
0.19 ± 0.03
0.60 ± 0.05
1.0
3.6 (2.4-5.3)
<0.001
Balloon diameter 
Consistent (40 mm)
Incremental (30-35-40mm)
Other
212
63
61
70
16
25
0.24 ± 0.03
0.27 ± 0.07
0.39 ± 0.06
0.32 ± 0.04
0.37 ± 0.09
0.42 ± 0.07
1.0
0.1 (0.6-1.9)
1.3 (0.8-2.0)
0.63
Manometry 3 months after 
treatment
LES p ≤ 10 mm Hg
LES p > 10 mm Hg
82/251
169/251
15
61
0.17 ± 0.04
0.25 ± 0.03
0.19 ± 0.05
0.33 ± 0.04
1.0
1.9 (1.1-3.3)
0.03
Total 336 111 0.28 ± 0.03 0.34 ± 0.03
Table 2 Distribution of patient and treatment characteristics in relation to recurrence of achalasia. Hazard ratios were calculated in univariate 
Cox regression analysis.
(LES p = lower esophageal sphincter pressure, CI = confidence interval, SE = standard error).
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figure 2 Relative hazard of recurrence of achalasia and LES-pressure 3 months after PD. 
The risk of recurrence increases linearly above a threshold value of 12 mm Hg. 
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figure 3 Relative hazard of recurrence of achalasia and age at diagnosis.
The risk of recurrence increases linearly below a treshold value of 50 years.
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dISCuSSIOn
Patients with achalasia are in many countries primarily treated with pneumatic dilation, as 
this is considered to be a safe and efficient treatment for this condition. Several studies have 
reported success rates of pneumatic dilatation between 35% and 85% 4-11. These highly vari-
able results hamper the use of pneumatic dilatation as primary treatment for achalasia. 
Variation of success rates is possibly due to different periods of follow-up with a gradual 
decrease in persistent success rates over time. In a study on 72 patients with a mean follow-
up of 6.5 years, the risk of recurrence after pneumatic dilatation remained as low as 15% 10. 
Another study showed a persistent treatment success rate of 60% for a patient population 
followed for 5-9 years post-pneumatic dilatation and 40% for patients followed more than 
15 years post-pneumatic dilatation 7. Our results fit within the above mentioned range of 
success. However, given the long follow-up period in our study, we were able to show that 
the rate of recurrence does indeed increase over time.
Another factor that impairs the direct comparison of different study results is the variable 
definition of recurrence and success. In some studies, recurrence was defined as symptom 
recurrence, sometimes based on a symptom score questionnaire like the Eckardt score, 
whereas other studies divided the data on the effectiveness of treatment into four classes 
according to Vantrappen and Hellemans 7, 18. This classification is based on symptoms of dys-
phagia (duration and frequency), regurgitation and weight loss. Others defined success as the 
absence of the need for further treatment 10. Against this background, we consider our strict 
protocol of follow-up after pneumatic dilatation one of the strengths of our study. In case 
of symptom recurrence we performed an upper GI endoscopy, a timed barium esophagram 
and a manometry. With this approach, we aimed to confirm an increase in LES-pressures in 
comparison to previous measurements, thus necessitating repeated treatment. 
We deliberately used a clinical definition for persistence and recurrence because this is most 
applicable and useful in the daily management of achalasia patients. Manometry pressures, 
timed swallow, or symptoms alone are insufficient tools to diagnose recurrence and repeat 
pneumatic dilatation or proceed to surgery. Our definition of recurrence was deliberately 
chosen for optimal clinical management and to prevent misdiagnoses. 
Another variable factor in literature concerning pneumatic dilatation is the distension 
protocol used. Until now there has been no strict, uniformly accepted pneumatic dilatation 
protocol for achalasia. Some investigators only perform one dilatation 8, others perform sev-
eral dilatations with incremental diameter of the balloon, or one dilatation at baseline and 
every couple of weeks after first dilation re-dilatation until clinical remission is achieved 5, 7, 19. 
In a retrospective study in a group of 75 achalasia patients, graded dilatation was found to be 
more effective than a single dilatation 20. In the present study baseline pneumatic dilatation 
was performed on 3 consecutive days with balloons of either the same diameter, or incre-
mental (30, 35, and 40 mm) diameter. According to the distension protocol, the majority of 
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the patients underwent 3 consecutive dilatations with a balloon diameter of 40 mm (n=212) 
or were treated with balloons with increasing diameter, respectively 30, 35 and eventually 40 
mm (n=63). There was no significant difference between both groups with respect to the risk 
of recurrence.   
This study shows that 111 out of 336 patients treated with one series of 3 pneumatic 
dilatation sessions developed recurrence of achalasia requiring further treatment. These first 
recurrences occurred at a mean interval of 51 months after baseline treatment. The 5-year 
risk of recurrence is 28%. In one study with a variable dilatation protocol consisting of one to 
three initial pneumatic dilatation sessions, a 5-9 year success of 60% was found after treat-
ment with pneumatic dilatation 7. In another study, in which the investigators performed one 
baseline pneumatic dilatation followed by on-demand strategy every 2-3 weeks till clinical 
remission was achieved, a 5-year persistent success of 67% was reported 5. These studies 
are in contrast with a study from German investigators which reported no more than 40 % 
persistent remission five years after one baseline pneumatic dilatation 8. In comparison with 
these studies, our 5-year risk of recurrence is relatively low.
After pneumatic dilatation, all patients in the present study had a strict schedule of follow-
up at 3, 12, 24 months and then every 2 years. Surveillance included upper GI-endoscopy, 
manometry and timed barium esophagram. After 8 years of follow-up surveillance included 
upper GI-endoscopy, further examination was performed on indication. In another study, 
patients were not routinely followed up after pneumatic dilatation, but were advised to make 
an appointment when symptoms recurred 7. We believe that symptoms alone are not reliable 
in assessing treatment success, but objective assessment of treatment and symptoms are 
required to achieve a higher treatment success. Patients are used to have a certain level of 
discomfort due to achalasia. Therefore this group of patients will not present themselves in 
an early phase of recurrence of disease.
In several studies risk factors for symptom recurrence after pneumatic dilatation have been 
identified. These factors were mainly young age (< 40 years), a post-treatment LES pressure 
above 10 mm Hg and a short period of symptoms prior of treatment 5, 6, 8, 12. A severely dilated 
esophagus (>80 mm) has been reported to be associated with poor outcome 4, 21. 
We found age to be a predictive factor in treatment outcome. Patients younger than 50 
years responded less well to pneumatic dilatation. The risk of recurrence increased linearly 
in patients with an age below 50 years. High recurrence percentages were found in patients 
younger than 21 years as the 5-year and 10-year risk of recurrence were 64% and 72%, re-
spectively.
In one study achalasia was categorized into 3 subtypes; type I as classic achalasia, type 
II as achalasia with esophageal compression, and type III as achalasia with spastic contrac-
tions. This study analysed treatment outcome in 83 patients and showed each subtype to 
be distinct in their responsiveness to therapy. Type III was a predictor of negative treatment 
response 22. The current study differentiated achalasia in 2 subtypes, classic achalasia (type 
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I) and vigorous achalasia (type II). This differentiation could be made in 288 patients. We 
showed that classic achalasia was associated with a higher risk of recurrence.
In several studies treatment response was associated with low LES pressures post-dilatation. 
The most optimal response was found in patients with a post-dilation LES pressure lower 
than 10 mm Hg 8, 11, 14. The current study confirms that a low LES pressure post-dilatation is 
associated with a good clinical outcome and shows that a LES pressure of < 12 mmHg at 3 
months post-dilatation is associated with a significant lower risk of recurrence. We therefore 
recommend the performance of a manometry at 3 months post-dilatation to measure LES 
pressure as a predictor of treatment outcome. 
Incomplete obliteration of the balloon’s waist was found to be a significant predictor of 
clinical outcome as this subgroup showed a significant higher risk for the development of re-
currence. In comparison with patients with complete obliteration, patients without showed 
a hazard ratio of 3.6.
In the present study the presence of dilation of the esophagus was not associated with 
increased risk of recurrence; however, we only scored the parameter dilation/no dilation but 
did not grade the severity of esophageal dilation. This does not exclude the possibility that 
the level of severity of dilation could correlate with the risk of recurrence. 
In a study from the US, investigators showed that patients with a longer duration of 
symptoms before diagnosis had a more tortuous esophageal body and tended to have an 
increased esophageal diameter observed by radiography 23. It can be hypothesized that early 
detection of recurrent disease and repeated treatment in an early stage may prevent (further) 
esophageal decompensation. Further investigation needs to be performed to confirm this 
hypothesis. 
There are a few shortcomings to our study. Firstly, we did not correlate improved emptying 
on a barium esophagram independently with symptom relief, LES pressures, and relapse 
rates. Secondly, our pneumatic dilatations stopped at a pressure of 300 mmHg. We did not 
increase the balloon pressure till complete obliteration of the balloon waist was achieved 
in all patients. Therefore our results are not the ultimate standard that can be achieved by 
pneumatic dilatation treatment. Further studies have to show whether differentiation of the 
approach, for example higher pressure, can improve results without increasing complication 
rates.
Several studies have compared surgery and pneumatic dilatation for the treatment of 
patients with achalasia 19, 24-27. 
In one of these studies 30.3% of patients initially treated with surgical myotomy had an-
other intervention after 5 years and 37.5% of patients had a subsequent intervention 10 years 
after initial therapy. In our study we obtained similar results with pneumatic dilatation, with 
a 5 and 10-year recurrence rate of 28% and 34% respectively. 
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A recently published systemic review showed that laparoscopic myotomy combined with 
an antireflux procedure provided better symptom relief (90%) than all endoscopic and other 
surgical approaches, with a low complication rate (6.3%) 28. 
Recently, a large European prospective randomised study compared laparoscopic Heller 
myotomy versus pneumatic dilatation as baseline treatment in 200 achalasia patients 29. One 
hundred and six patients were treated with laparoscopic Heller myotomy with Dor fundo-
plication and 94 patients were treated with pneumatic dilatation. After two years of follow-
up, both treatments had a comparable success rate of 92 versus 87%. Further follow-up is 
required to evaluate long-term outcome. The long-term outcome of this study should further 
determine which therapy should be reserved for different subgroups of achalasia patients as 
baseline therapy.
COnCLuSIOn
Pneumatic dilatation is an effective treatment for achalasia, but recurrence rates after pneu-
matic dilatation increase over time. Young age at presentation, classic achalasia, incomplete 
obliteration of the balloon’s waist during dilatation, and high LES pressure at 3 months after 
pneumatic dilatation are independent predicting factors for the need of repeated pneumatic 
dilatation during follow-up. These factors should be taken into account in the follow-up 
strategy of achalasia patients, leading to a stricter follow-up protocol in patients with the 
above-mentioned predicting factors. Such a protocol should aim for timely detection of re-
currence (defined as symptom recurrence in combination with objective parameters such as 
a significant increase in LES pressure) with renewed, tailored treatment. Our results show that 
most patients are then eligible for renewed pneumatic dilatation. However, selected cases 
such as those 21 years of age or younger may in case of recurrence be referred for surgery 
earlier. 
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ABSTRACT
Introduction: The etiology of achalasia is still unknown but there is some evidence for a 
genetic or auto-immune pathofysiology. In this case one should expect familiar clustering of 
achalasia and an association between achalasia and other auto-immune diseases. 
Methods: In a large cohort of achalasia patients with long term follow-up we studied the 
familiar prevalence of achalasia and the prevalence of auto-immune thyroid diseases by 
means of a questionnaire send to the patient and their general practitioner. Patients older 
than 75 years were excluded.
Results: Out of the 239 patients with achalasia still under surveillance, 158 were suitable 
for including in this study. One-hundred-fifteen (73%, 60 male, mean age 52 years range 
18-74) patients returned the questionnaire. All general practitioners returned the question-
naire. Nine (7.8%) patients suffered from thyroid disease. Compared to the age and gender 
identical overall population the odds ratio for the presence of autoimmune thyroid disease in 
achalasia patients was 6.58 (3.42 – 12.66) (p< 0.001). Also other auto-immune diseases were 
reported but more scarcely.
Four (3.5%) patients reported a first degree relative and 2 (1.7%)  patients a second degree 
relative with symptoms compatible with achalasia but none of these relatives had been 
diagnosed with or treated for achalasia.  
Conclusion: This study in a large group of achalasia patients does confirm the hypothesis 
that achalasia patients are more prone to auto-immune thyroid disease but does not suggest 
a familial clustering of the disease.
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InTROduCTIOn
Achalasia is a motor disease of the esophagus in which aperistalsis and incomplete or absent 
LES relaxation leads to a functional esophageal obstruction. The etiology of this disease is still 
largely unknown and therefore treatment is purely symptomatic and aims at reducing the 
LES pressure by pneumatic dilatation or laparoscopic myotomy1. The impaired esophageal 
motility with resulting chronic stasis as well as the dilation therapy with resulting gastro-
esophageal reflux give rise to mucosal inflammation2, which increases the risk for esophageal 
cancer3 
Esophageal resection specimen of patients with achalasia have revealed inflammation 
around the myenteric plexus 4. It is also known that the neurons containing nitric oxide are 
absent in the myenteric plexus in patients with achalasia. Nitric oxide is implicated in the 
inhibitory response of the lower esophageal sphincter5. The inflammatory infiltrate within 
the myenteric plexus predominantly contains T-lymfocytes (CD3 positive) 4, 6. This has led to 
the hypothesis that an autoimmune process may underlie achalasia leading to an inflamma-
tory process and neuronal cell loss. HSV-1 viral antigen have been proposed as evoking agent 
but due to conflicting evidence the exact etiology remains to be determined 7-9.
The observation that achalasia can occur at every age but shows two incidence peaks at 
30 – 40 years and after 60 years of age supports the auto-immune hypothesis 10.  The similar 
prevalence of achalasia in men and women may be an argument against.
If the disease has an autoimmune etiology, one should expect that other auto-immune 
diseases, of which auto-immune thyroid disease is the most common, appear more often in 
patients with achalasia compared to the overall population. 
There is also some evidence for a genetic basis for achalasia 11. Some case-control series 
have described associations with certain polymorphisms within the IL23R  and NOS2A gene 
12, although the latter could not be confirmed in a large series. 13
For this reasons, we studied the prevalence of other auto-immune diseases, especially 
auto-immune thyroid disease and the prevalence of achalasia in first and second degree 
relatives in a large cohort of achalasia patients.
MATERIAL And METhOdS:
Patients
This is a single centre, cross sectional clinical study performed in a university medical centre 
which since long serves as a tertiary referral centre for treatment and surveillance of patients 
with achalasia. Our clinical protocol has been described before1. In brief, the diagnosis was 
based on results from upper gastro-intestinal endoscopy, esophageal manometry and timed 
barium esophagram. All patients were offered treatment with pneumatic dilatation and kept 
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under follow-up. The first years of follow up consisted of regular endoscopy, manometry and 
timed barium esophagram. After 7 years only surveillance endoscopy was performed. 
For this study, patients under 75 years of age still under endoscopic surveillance were 
eligible for inclusion. These patients were asked to complete a self-developed questionnaire 
which focused, amongst others, on co-morbidity and familiar occurrence of achalasia. In-
formed consent was asked to contact the general practitioner. Patients, who did not return 
the questionnaire within 8 weeks, received a reminder. A short questionnaire was sent to the 
general practitioner with the questions whether the patient suffered from thyroid or other 
auto-immune diseases and if so, when this diagnosis was made. When one of the completed 
questionnaires raised additional questions the patient or treating doctor was called. 
The prevalence of thyroid disease was compared to the age and sex adjusted overall 
population as reported in a Dutch national survey on the prevalence and incidence in gen-
eral practice14. 
Statistics:
The prevalence of thyroid auto-immune disease was compared with the prevalence reported 
in general practice. A comparison of age en sex matched prevalence of thyroid disease 
between achalasia patients and this control group was made in SPSS, using log linear regres-
sion. The odds ratio was calculated based on a model distinguishing patients and the general 
population, corrected for age and gender.
RESuLTS:  
Of the 239 patients currently under surveillance, 81 patients were excluded for reasons of 
age. The remaining 158 (67%) patients were eligible for inclusion and asked to complete 
the questionnaire. Seventy-three percent of the eligible patients returned the questionnaire 
(115/159, M/F 60/55). The mean age of the participants was 52 years (range 18-74). The mean 
duration of disease was 19 years (2-61). Mean age at diagnosis had been 33 years (range 
3-67). 
The mean age and gender of the 44 non-responders (M/F 21/23, mean age 50 (20-73) 
years) did not differ from the responders.   
Seven (6%) patients reported to suffer from thyroid disease (5 hypo- and 2 hyperthyroid-
ism). The general practitioners confirmed all diagnosis. This survey for confirmatory general 
practice data revealed two additional patients with hypothyroidism which brought the total 
prevalence of thyroid disease in our cohort of achalasia patients to 7.8% (9/115 patients). The 
age- and sex-matched prevalence of thyroid disease in Dutch general practice was 0.9%. As 
such the odds ratio for the association between achalasia and thyroid disease was 6.58 (Con-
fidence interval 3.42 – 12.66) (p <0,001). This indicates that the prevalence of auto-immune 
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thyroid disease is more than six times higher in a cohort of achalasia patients compared to 
the overall population.
In five patients the thyroid disease was diagnosed before achalasia was. In the other 4 
patients the thyroid disease developed later during follow-up. (Table 1) 
Two patients (1.7%) reported Addison’s disease, one of them suffering from the Allgrove 
syndrome or Triple A syndrome consisting of the combination of achalasia, Addison and 
alacrimia, a rare autosomal recessive congenital disorder. Three patients (2.6%) suffered from 
rheumatoid arthritis and 2 (1.7%) patients from Crohn’s disease both in combination with 
Bechterew’s spondylarthropathy. One patient was known with idiopathic trombocytopenic 
purpura (ITP). (Table 2) Four patients (3.5%) reported to have diabetes, one insuline depen-
dent.
Six (5.2%) patients reported a first- or second degree (n=4, resp 2) relative with symptoms 
compatible with achalasia but none of them had actually been diagnosed with achalasia. 
The cohort included three twins. None of these sibs had symptoms of achalasia. 
The latest reported incidence of achalasia in a Western country is 1.63 per 100.000 and 
prevalence of 10.82 per 100.000.15 Therefore our cohort is too small to study familial prepon-
derance.
Patient sex Thyroid disease Age achalasia diagnosis Age thyroid disease diagnosis
1 Female hypothyroidism 18 37
2 Female hypothyroidism 41 38
3 Female hyperthyroidism 67 64
4 Female hypothyroidism 56 54
5 Female hypothyroidism 64 <64
6 Female hyperthyroidism 58 63
7 Female hypothyroidism 39 37
8 Female hypothyroidism 27 49
9 female hypothyroidism 53 56
Table 1: age at diagnosis of achalasia and thyroid disease
Total patients n (%)
Thyroid 9 (7.8%) (OR 6.58) (CI 3.42 – 12.66) P<0.001
Hyperthyreoidism 2
Hypothyreoidism 7
Addison’s disease 2  (1.7%)
Allgrove syndrome 1
Reumatoid arthritis 3 (2.6%)
Crohn’s disease 2 (1.7%)
M Bechterew 2 (1.7%)
ITP 1 (0.87%)
Table 2: prevalence of auto-immune diseases 
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dISCuSSIOn:
One hypothesis for the etiology of achalasia assumes that a viral infection elicits an auto-
immune response in an genetically susceptible patient 16. However  this hypothesis has so far 
never been proven, not in general nor for specific viral infections such as herpes simplex and 
human papilloma viruses 9. 
The literature regarding potential associations between achalasia and other auto-immune 
diseases is also sparse. Several case reports reported co-occurrence of achalasia and auto-
inflammatory or –immune conditions such as auto-immune thyreotoxicosis 17, myasthenia 
gravis and polymyositis 18, 19.  In two cohorts of 30 respectively 44 achalasia patients, the 
prevalence of achalasia ranged between 20% and 23% 20, 21. Recently a paper from Canada, 
investigating auto-immune conditions in 193 patients with achalasia reported an odds ratio 
of 8.5 for hypothyreoidism. This study was based on retrospective chart review. Comparison 
was made with the overall population but the achalasia patients were 10-15 years older than 
the controls and the achalasia cohort contained more men 22.  We used the age and gender 
specific prevalence of the general practice and compared these with the data delivered by 
the general practitioners of the achalasia patients. Therefore our odds ratio is lower (6.58 
versus 8.5) but likely to be more realistic. 
In our cohort of patients with achalasia the prevalence of auto-immune thyroid disease 
was more than 6-times larger than in the overall population, corrected for age and sex. This 
finding supports the hypothesis that achalasia has an auto-inflammatory component. The 
observation of a variety of other auto-immune diseases in 15 (10%) of our patients is of inter-
est and further supports the link with an auto-inflammatory mechanism. 
This underlies the importance for further research into the underlying mechanism. If the 
auto-immune etiology is strengthened, this might have consequences for the treatment of 
achalasia. Treatment nowadays is purely mechanistic consisting of LES-pressure lowering 
therapy by means of pneumatic dilatation or laparoscopic myotomy, which focuses on man-
aging the symptoms instead of the cause1. One can argue that immunosuppressive therapy 
should be considered in early achalasia23. If the inflammation at the level of the myenteric 
plexus can be suppressed, esophageal motility might restore. However patients with acha-
lasia usually present in the later phase of the disease when the plexus is severely damaged 
or even destroyed and it is unlikely that immunosuppressive therapy can help at that stage.
Given this high prevalence of thyroid disease, it is reasonable to screen achalasia patients 
for thyroid diseases and be attentive of symptoms of other auto-inflammatory diseases. A 
comparison can be made with celiac disease in which the prevalence of thyroid disease is 
around 10%  and regular TSH screening is widely accepted24.  
Achalasia in relatives other than in the Allgrove syndrome is very scarcely reported and 
probably the older publications of familial achalasia 25-35 indeed includes patients with 
Allgrove syndrome as this syndrome was first described in 197836. In our cohort no first- or 
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second-degree relatives had actually been diagnosed with or treated for achalasia even 
though several were reported to have symptoms compatible with achalasia. It will be of 
interest to perform a further survey in the near future to see whether part of these subjects 
will have been diagnosed with achalasia by then. 
COnCLuSIOn
Patients with achalasia are more likely to suffer from auto-immune thyroid disease than 
matched controls. This supports the hypothesis that achalasia has an underlying auto-
inflammatory component. We could not confirm a familiar clustering of achalasia.
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Achalasia is a rather rare motility disorder of the esophagus characterized by a non-relaxing 
lower esophageal sphincter in combination with esophageal aperistalsis leading to chronic 
food stasis. Without treatment this stasis causes esophageal dilatation and elongation and 
eventually can lead to a decompensated esophagus. Fermentation of retained food affects 
the esophageal mucosa causing inflammation. This inflammation leads to proliferation and 
can cause multifocal dysplasia and in some patients leads to the development of squamous 
cell carcinoma. 
Treatment of achalasia is purely symptomatic and aims at lowering of the pressure in the 
lower esophageal sphincter. Adequate treatment may restore food passage, yet simultane-
ously caries a risk of inducing gastro-esophageal reflux, which can induce development of 
Barrett’s epithelium and eventually esophageal adenocarcinoma. These aspects are further 
discussed and outlined in chapter 2.
In chapter 3 esophageal biopsy samples obtained during endoscopic surveillance after 
pneumatic dilatation were studied for the presence of inflammation. The histological find-
ings were compared to the endoscopical report. Forty percent of the achalasia patients 
developed histological chronic active or ulcerating esophagitis after LES-lowering treatment. 
The sensitivity of endoscopy to detect inflammation was poor, partly explained by impaired 
visibility due to mucosal adherence of food. There was a clear association between histo-
logical inflammation and food stasis seen at endoscopy. Since the sensitivity of endoscopy 
to detect inflammation is low, surveillance endoscopy with biopsy sampling and assessment 
of stasis is warranted to detect inflammation and early neoplastic changes. Efforts should be 
made to optimize the conditions for endoscopy by prescription of a liquid diet for 2-3 days 
before surveillance endoscopy to obtain a better view. One can argue that severe inflamma-
tion or food stasis at surveillance endoscopy are arguments for a more aggressive treatment 
protocol even if the patient denies deterioration of symptoms. 
In chapter 4 the risk of esophageal cancer development in longstanding achalasia treated 
with pneumatic dilatation was studied. In a cohort of 448 patients with a mean follow-up of 
9.6 years, 15 (3.3%) patients developed esophageal carcinoma. The hazard ratio to develop 
esophageal cancer was 28 (CI 17-46). The risk to develop esophageal cancer rose with the 
length of follow-up and the duration of symptoms. After a follow up of 20 years, the pro-
portion of patients developing an esophageal carcinoma had risen to approximately 10%. 
This explains our expectation that the hazard ratio for development of esophageal cancer in 
the presence of achalasia will continue to increase with further follow-up. The risk of cancer 
development is similar to the risk of cancer development in Barrett’s metaplasia for which 
surveillance is widely accepted. Therefore surveillance in longstanding achalasia should be 
considered, although the optimal surveillance strategy needs to be defined. In our cohort 
only 5 (33%) patients were detected at a curable state. Optimization of surveillance might 
be facilitated by the use of histological markers. For that purpose, we studied in chapter 
5 the use of markers in surveillance biopsy samples.  Surveillance biopsies of patients who 
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eventually developed esophageal carcinoma were studied for p53 and ki67 expression using 
immunohistochemistry. These were compared with the surveillance biopsy samples from 10 
patients with achalasia without cancer development during similar length of observation. 
Ki67, a proliferation marker was positive in a large amount of samples and did not differ be-
tween cancer patients and controls. This is likely a result of hyperproliferation caused by food 
stasis. P53 however was positive in 82% of the patients at a mean of 6 years before cancer 
development compared with 10% in the control patients. We therefore concluded that P53 
may be used to identify achalasia patients with the highest risk of developing malignancy.  
Chapter 6 focused on the risk of development of Barrett’s metaplasia. Although it seems 
reasonable to consider achalasia and Barrett’s metaplasia as two opposing ends of a spectrum 
we actually showed that there is an association between these two conditions. Treatment 
of achalasia leading to a low LES-pressure may induce gastro-esophageal reflux leading to 
Barrett’s esophagus and esophageal adenocarcinoma. Barrett’s metaplasia in achalasia is 
however scarcely reported, probably because surveillance endoscopy is rarely performed. 
Barrett’s esophagus is also incidentally found in untreated patients, in which case achalasia 
was likely to develop independent from, yet after, the development of Barrett’s metaplasia. In 
our cohort of 331 patients with achalasia treated with pneumatic dilatation 8.4% of patients 
developed Barrett’s metaplasia. It was remarkable that patients with a hiatal hernia carried 
the highest risk for Barrett’s development. The development of Barrett’s metaplasia forms an 
extra argument to perform surveillance endoscopies. The patients with Barrett’s metaplasia 
or a hiatal hernia should be offered a more intensive surveillance protocol. 
Chapter 7 focused on pneumatic dilatation.  Pneumatic dilatation is a safe and effective 
therapy strategy. In a period of 32 years, 336 patients were treated primarily with pneumatic 
dilatation with increasing balloon size (30, 35 and 40 mm) on 3 consecutive days. The perfora-
tion risk was 1.3% without mortality. The 5-years risk of recurrence was 28%, with the first 
recurrence occurring after a mean interval of 51 months. As follow-up lengthens the recur-
rence rate increases. Age is a predictive factor in treatment outcome. Patients younger than 
50 years responded less to pneumatic dilatation. In patients younger than 21 years the 5-year 
and 10-year risk of recurrence was even 64% and 72% respectively. Other predictive factors 
are classic achalasia which was associated with a higher recurrence risk as are LES pressure 
three months after pneumatic dilatation higher than 12 mmHg and incomplete obliteration 
of the balloon waist. 
Chapter 8 reports on the co-incidence of achalasia and auto-immune thyroid disease. 
Since the etiology of achalasia is still unresolved, treatment is purely symptomatic aiming at 
reducing the LES-pressure to improve passage of food. However, there is some evidence that 
achalasia is an autoimmune disease. If this is true, a coincidence with other auto-immune 
diseases is expected. The prevalence of autoimmune thyroid disease was studied and com-
pared to the prevalence in the overall population. In our cohort indeed a higher prevalence 
of auto-immune thyroid disease was found (OR 6.58 (3.42 – 12.66)). Also other auto-immune 
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diseases were reported. This finding supports the auto-immune hypothesis. A familiar oc-
currence, which is also common in auto-immune diseases, could not be detected. This is 
probably due to the cohort size, which is too small to study a familiar clustering of a disease 
with a very low prevalence.
In conclusion achalasia is a rare motility disorder with evidence for an autoimmune etiology 
as autoimmune thyroid diseases appear more common in patients with achalasia. However 
this observation has not lead to causative treatment. Treatment is still symptomatic at lower-
ing the lower esophageal sphincter pressure. 
Pneumatic dilatation is an effective LES pressure lowering treatment module, however 
young age, classic achalasia, high LES-pressure 3 month after PD and incomplete oblitera-
tion of the balloon’s waist are important predictors for the need of repeated treatment and 
alternative treatment as surgery should in these cases be considered.
Patients with achalasia have a considerable risk to develop esophageal carcinoma, which is 
often detected in a late incurable state. Efforts should be made to define those patients with 
the highest risk, who could benefit from a more intense surveillance protocol. Long lasting 
disease, p53 overexpression and inflammation in esophageal surveillance biopsy samples, 
food stasis at endoscopy and development of Barrett’s metaplasia appeared to be indepen-
dent risk factors. Future research should focus on the best surveillance interval and strategy. 
The patients with risk factors should be offered a, probably annual, surveillance endoscopy 
starting 10 years after onset of symptoms. To improve the yield of a surveillance endoscopy 
the esophagus should be properly cleaned by prescribing the patients with food stasis a 
liquid diet 2-3 days before endoscopy. 
In case of food stasis at endoscopy or severe inflammation in the surveillance biopsy 
samples retreatment should be considered even in the absence of deterioration of symptoms 
as these are important risk factors. 
To prove this strategy, a prospective randomized study is needed but will be hard to per-
form. Therefore it is important to cluster and follow achalasia patients by a strict protocol, to 
study the cancer risk as follow-up lengthens and to study the outcome of a more intensive 
surveillance and treatment protocol. 
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Achalasie is een vrij zeldzame aandoening van de slokdarm, welke wordt gekarakteriseerd 
door een niet of onvoldoende relaxerende onderste slokdarmsphincter in combinatie met af-
wezige slokdarmperistaltiek. Tezamen leidt dit tot klachten van een functionele slokdarmob-
structie met chronische stase van voedsel. Zonder behandeling kan deze voedselstase leiden 
tot dilatatie en elongatie van de slokdarm en uiteindelijk zelfs tot een gedecompenseerde 
slokdarm. Fermentatie van geretineerd voedsel heeft een etsend effect op de slokdarm 
mucosa en veroorzaakt ontsteking. Deze chronische ontsteking veroorzaakt proliferatie en 
kan uiteindelijk leiden tot multi-focale dysplasie en in sommige patiënten zelfs tot de ontwik-
keling van een plaveiselcelcarcinoom van de slokdarm. 
De behandeling van achalasie is puur symptomatisch en gericht op het verlagen van de 
druk in de onderste slokdarmsphincter. Adequate behandeling kan de voedselpassage ver-
beteren maar zal tegelijkertijd een risico inhouden op het ontstaan van gastro-oesofageale 
zure reflux, welke het ontstaan van Barrett’s metaplasie en uiteindelijk zelfs de ontwikkeling 
van een adenocarcinoom kan induceren. Deze aspecten werden verder uitgewerkt en bedis-
cussieerd in hoofdstuk 2.
In hoofdstuk 3 werden slokdarmbiopten, die zijn verkregen in het kader van surveillance 
na pneumodilatatie, opnieuw beoordeeld op de aanwezigheid van ontsteking. Deze histolo-
gische bevindingen werden vergeleken met de bevindingen gerapporteerd in het endosco-
pie verslag. Veertig procent van de patiënten met achalasie ontwikkelde chronisch actieve 
of ulcererende oesofagitis in de biopten na hun behandeling voor achalasie. De sensitiviteit 
van endoscopisch onderzoek om ontsteking vast te stellen bleek slecht, deels verklaard door 
bemoeilijkte endoscopische inspectie als gevolg van voedselstase en voedselbeslag op de 
mucosa. Er blijkt een duidelijke associatie aanwezig tussen de histologische ontsteking en de 
voedselstase vastgesteld bij endoscopisch onderzoek.
Aangezien de sensitiviteit van endoscopisch onderzoek om ontsteking te detecteren laag 
is, is surveillance endoscopie met het nemen van biopten en het objectiveren van voed-
selstase aangewezen om ontsteking en vroege neoplastische veranderingen op te sporen. 
Maatregelen zoals het voorschrijven van een vloeibaar dieet 2-3 dagen voor endoscopisch 
onderzoek zijn nodig om de inspectie van de mucosa te optimaliseren. Het is te overwegen 
om in het geval van ernstige ontsteking in de biopten of voedselstase bij surveillance endo-
scopie een agressievere houding aan te nemen en aanvullende behandeling te overwegen 
zelfs indien de patiënt geen duidelijke toename van zijn klachten aangeeft.
In hoofdstuk 4 werd het risico op het ontwikkelen van een slokdarmcarcinoom voor pati-
enten met lang bestaande achalasie na pneumodilatatie bestudeerd. In ons cohort van 448 
patiënten met een gemiddelde follow-up van 9,6 jaar ontwikkelden 15 (3,3%) patiënten een 
slokdarmcarcinoom. De hazard ratio om een slokdarmcarcinoom te ontwikkelen bedraagt 28 
(95% betrouwbaarheidsinterval 17-46). Het risico om een slokdarmcarcinoom te ontwikkelen 
neemt toe met de lengte van de follow-up en de duur van de klachten. Na een follow-up van 
20 jaar loopt het percentage patiënten, dat een slokdarmcarcinoom ontwikkelt, zelfs op tot 
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ongeveer 10%. Het is te verwachten dat de hazard ratio verder zal oplopen als de duur van 
follow-up langer wordt. 
Het risico op het ontwikkelen van een slokdarmcarcinoom voor patiënten met achalasie 
is vergelijkbaar met het ontwikkelen van een carcinoom bij patiënten met een Barrett’s 
metaplasie, waarvoor surveillance algemeen is geaccepteerd. Daarom moet surveillance bij 
patiënten met langdurige achalasie sterk overwogen worden, hoewel de optimale surveil-
lance strategie nog zeer onduidelijk is. In ons cohort werden namelijk ondanks een 3-jaar-
lijkse surveillance slechts 5 (33%) patiënten gediagnosticeerd in een resectabel stadium. 
Voor het optimaliseren van surveillance zouden wellicht histologische markers gebruikt 
kunnen worden. Met deze vraagstelling werd in hoofdstuk 5 het gebruik van markers op 
surveillance biopten verder bestudeerd. Surveillance biopten van patiënten die uiteindelijk 
een slokdarmcarcinoom ontwikkelden werden onderzocht op expressie van p53 en ki67 
met behulp van immunohistochemisch onderzoek. Deze gegevens werden vergeleken met 
surveillance biopten van 10 patiënten met achalasia die gedurende een vergelijkbare follow 
up lengte geen carcinoom ontwikkelden. 
Ki67 is een proliferatiemarker en bleek positief in een groot aantal biopten zonder ver-
schil tussen patiënten die kanker ontwikkelden en de controle groep. Dit is waarschijnlijk 
het gevolg van hyperproliferatie veroorzaakt door chronische voedselstase en ontsteking. 
P53 echter, bleek positief in 82 % van de patiënten die uiteindelijk kanker ontwikkelden 
vergeleken met 10% in de controle groep. We concludeerden dat p53 gebruikt kan worden 
om de achalasia patiënten met het hoogste risico op het ontwikkelen van een maligniteit te 
identificeren. 
hoofdstuk 6 focust op het risico op het ontwikkelen van Barrett’s metaplasie. Hoewel 
het logisch lijkt om achalasie en Barrett’s oesofagus als twee tegenovergestelde uiteinden 
van een spectrum te zien hebben we aangetoond dat er een associatie bestaat tussen 
beide aandoeningen. Behandeling van achalasie gericht op het verlagen van de druk in de 
onderste slokdarmsphincter kan gastro-oesophageale reflux veroorzaken, leidend tot Bar-
rett’s metaplasie en adenocarcinoom van de slokdarm. Barrett’s metaplasie bij patiënten met 
achalasie is slechts schaars beschreven, waarschijnlijk omdat surveillance bij achalasia weinig 
wordt verricht. Verrassenderwijs is Barrett’s metaplasie ook enkele malen gerapporteerd bij 
patiënten met achalasie die nog niet behandeld zijn. Achalasie lijkt zich dan onafhankelijk 
van of na het ontstaan van de Barrett te ontwikkelen. In ons cohort van 331 patiënten met 
achalasie, die hoofdzakelijk met pneumodilatatie zijn behandeld ontwikkelde 8,4% van de 
patiënten Barrett’s metaplasie. Het was opvallend dat de patiënten met een hiatus hernia 
het hoogste risico hadden op het ontwikkelen van Barrett’s metaplasie. De ontwikkeling van 
een Barrett’s slokdarm is een extra argument om surveillance uit te voeren bij patiënten met 
achalasie. De patiënten met Barrett of een hiatus hernia moeten mogelijk een intensievere 
surveillance aangeboden krijgen.
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hoofdstuk 7 onderzoekt pneumodilatatie. Pneumodilatatie is een veilige en effectieve 
behandelmethode. Gedurende een periode van 32 jaar werden 336 patiënten met achalasie 
in ons centrum primair behandeld met pneumodilatatie met opklimmende ballondiameter 
(30, 35 en 40 mm) op 3 opeenvolgende dagen. Het perforatierisico bleek laag 1,3% en zonder 
mortaliteit. Het 5-jaars risico op recidief klachten was 28% met het eerste recidief gemiddeld 
51 maanden na de behandeling. Bij oplopen van de follow-up duur neemt dit recidief risico 
toe. Leeftijd is een voorspellende factor voor de uitkomst van de behandeling. Patiënten 
jonger dan 50 jaar hebben minder (lang) effect van pneumodilatatie. Patiënten jonger dan 
21 jaar hebben zelfs een recidief risico van 64% en 72%, na 5 respectievelijk 10 jaar. Andere 
voorspellende factoren zijn klassieke achalasie, een rustdruk in de onderste sphincter van > 
12 mm Hg 3 maanden na behandeling en incompleet verstrijken van de taille in de ballon 
tijdens dilatatie. Deze factoren gingen alle gepaard met een hoger risico op recidief.
hoofdstuk 8 rapporteert de co-incidentie van achalasie en auto-immuun schildklierziek-
ten. Omdat de etiologie van achalasie nog niet is opgehelderd is de behandeling puur symp-
tomatisch en gericht op het verlagen van de rustdruk in de onderste slokdarmsphincter en 
verbeteren van de voedselpassage. Echter, er is enig bewijs dat achalasie een auto-immuun 
aandoening betreft. Als dit het geval is, dan zou er een hogere prevalentie van andere 
auto-immuun aandoeningen bestaan in de groep patiënten met achalasie. De prevalentie 
van auto-immuun schildklieraandoeningen werd onderzocht in onze groep patiënten met 
achalasie en vergeleken met de prevalentie in de algemene bevolking. In ons cohort werd 
inderdaad een hogere prevalentie auto-immuun schildklierziekte gevonden (Odds Ratio 
6,58 (3,42 – 12,66). Ook andere auto-immuun aandoeningen werden gerapporteerd. Deze 
bevindingen ondersteunen de auto-immuun hypothese. Een familiaire clustering, hetgeen 
ook vaak gebruikelijk is bij auto-immuun aandoeningen, kon niet worden gevonden. Dit is 
waarschijnlijk het gevolg van het feit dat het cohort relatief klein is om de familiaire clustering 
van een aandoening met een lage prevalentie te onderzoeken.
Concluderend is achalasie een zeldzame slokdarm motiliteits stoornis, die mogelijk een 
auto-immuun etiologie heeft aangezien auto-immuun schildklierziekten vaker voorkomen 
bij patiënten met achalasie. Deze observatie heeft echter niet geleid tot een oorzakelijk 
behandeling. De behandeling is nog steeds symptomatisch en gericht op het verlagen van 
de rustdruk van de onderste slokdarmsphincter. Pneumodilatatie is een effectieve therapie, 
hoewel jonge patiënten, patiënten met klassieke achalasie, patiënten met een hoge rustdruk 
in de onderste slokdarmsphincter 3 maanden na dilatatie en patiënten waarbij de taille 
van de ballon niet volledig verstrijkt tijdens dilatatie een slechtere respons hebben. In deze 
patiëntencategorie zal eerder gedurende de behandeling alternatieve therapie zoals laparo-
scopische myotomie moeten worden overwogen.
Patiënten met achalasie hebben een duidelijk verhoogd risico op het ontwikkelen van een 
slokdarmcarcinoom, welke vaak in een irresectabel stadium wordt gediagnosticeerd. Het is 
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van belang om de patiënten met het hoogste risico te definiëren omdat zij het meest gebaat 
zijn bij intensievere surveillance. 
Lang bestaande ziekte, p53 overexpressie en matig tot ernstige ontsteking in surveillance 
biopten, voedselstase en ontwikkelen van Barrett’s metaplasie bij surveillance scopie blijken 
risicofactoren te zijn. Onderzoek in de toekomst moet uitwijzen wat de beste surveillance 
methode en het beste interval is. Patiënten met risicofactoren zouden een waarschijnlijk 
jaarlijkse surveillance aangeboden moeten worden, 10 jaar na het ontstaan van de klachten. 
Om de opbrengst van deze scopie te optimaliseren moet de slokdarm goed schoon zijn, door 
het voorschrijven van een vloeibaar dieet gedurende 3 dagen voorafgaand aan de scopie.
In geval van voedselstase of ernstige ontsteking in de surveillance biopten moet her-
nieuwde behandeling (indien mogelijk) worden overwogen ook als patiënt geen evidente 
verslechtering aangeeft.
Om deze strategie te bewijzen is een prospectieve gerandomiseerde studie nodig wat 
moeilijk uit te voeren zal zijn. Het is echter belangrijk om patiënten met achalasie zoveel 
mogelijk te clusteren en te behandelen en vervolgen volgens een strikt protocol om het 
kankerrisico vast te stellen na nog langere follow-up en de uitkomsten van een intensievere 
surveillance en behandeling te onderzoeken.
.
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haar atheneum examen aan de Willem van Oranje scholengemeenschap te Oud-Beijerland. 
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dr. H.S.L.M Tjen). In 2003 kreeg zij de mogelijkheid de opleiding tot maag- darm- en lever-
arts op de afdeling MDL van het Erasmus Medisch Centrum te Rotterdam (opleider Prof. Dr. 
E.J. Kuipers) te volgen. Op 1 januari 2006 volgde registratie tot MDL-arts en sindsdien is zij 
werkzaam als MDL-arts in het Sint Franciscus Gasthuis te Rotterdam.
Gedurende de vervolgopleiding tot MDL-arts behandelde zij een groot cohort achalasie 
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E.J. Kuipers).
Ivonne Leeuwenburgh BW 3.indd   137 24-02-12   11:47
Ivonne Leeuwenburgh BW 3.indd   138 24-02-12   11:47
Dankwoord
Ivonne Leeuwenburgh BW 3.indd   139 24-02-12   11:47
Ivonne Leeuwenburgh BW 3.indd   140 24-02-12   11:47
141
Dankwoord
 
Dit proefschrift is mede tot stand gekomen door de hulp van heel veel mensen. Het is onmo-
gelijk iedereen persoonlijk te noemen maar ik wil er graag een paar uitlichten:
Allereerst natuurlijk richt ik mij tot mijn opleider en promotor prof. dr. E.J. Kuipers. Beste 
Ernst, nog als de dag van gisteren herinner ik mij het bizarre sollicitatiegesprek voor de ver-
volgopleiding MDL. Jij had snel iemand nodig met de interne vooropleiding op zak en ik had 
het idee om eerst internist te worden. Het leek de omgekeerde wereld. Jij droeg argumenten 
aan waarom ik de overstap moest maken en ik waarom ik dat niet zou doen. Maar tegen jouw 
enthousiasme en stimulerende pleidooi was ik niet bestand. Ik maakte de overstap en heb er 
geen moment spijt van gehad. Ik ben je erg dankbaar dat je doorzette en mij een plek in jouw 
opleiding gunde. Veel dank ook voor je geduld en je begrip in het trage tot stand komen van 
dit boekje. Een bezoek aan jou gaf steeds weer energie om door te ploeteren.
Dr. G.L. Ong, beste Evelien, wat ontzettend jammer dat je de totstandkoming van dit boekje 
niet mee mocht maken. Vele jaren heb je je ingezet en een prachtig cohort achalasie patiënt-
en opgebouwd. Met veel toewijding heb je de patiënten behandeld en alles uitstekend 
gedocumenteerd en gekopieerd in dummydossiers. Mede door dit complete archief was het 
mogelijk om dit onderzoek te verrichten. Ik ben ontzettend vereerd dat prof. dr. H.A. Bruining 
een bijzondere rol wil innemen en de verdediging wil voorzitten.
Prof. dr. P. D. Siersema, beste Peter, dank voor je hulp en adviezen bij de tot standkoming van 
hoofdstuk 6. Jij zorgde ervoor dat ik op het MDL- laboratorium terecht kon en er hulp kwam 
bij het maken en kleuren van de coupes. Monique, Astrid en Tom heel veel dank voor jullie 
uitleg en hulp bij het kleuren van de coupes en het uitvoeren van de controle tellingen.
Prof. dr. H.W. Tilanus, prof. dr. E.W. Steyerberg en prof. dr. A.J. Smout, dank voor het goed-
keuren van mijn manuscript en jullie deelname in de promotiecommissie.
Prof. dr. G. Boeckxstaens, dr S. Sleijfer en prof. dr. F.J.W. ten Kate, dank voor jullie deelname in 
de promotiecommissie.
Drs. J. Haringsma, beste Jelle, met veel geduld stond je naast me als ik de achalasie patiënten 
behandelde. Altijd met positieve feed-back. Je deed me geloven dat ik één van de beste 
endoscopisten was die je ooit had gezien (wat natuurlijk grote onzin was) en je bent een 
echte teacher. Ik mocht zelfs al na 8 maanden endoscopie-ervaring een pneumodilatatie 
doen op de live endoscopy day (we weten beiden de afloop…..) Dank voor je vertrouwen.
Dr. H. van Dekken, beste Herman, al weer vele jaren geleden zaten we samen achter de 
microscoop meer dan duizend slokdarmbiopten te bekijken en te scoren. Het moet je toch 
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wel de keel uitgekomen zijn maar dat heb je me nooit laten merken. Iedere coupe werd zeer 
nauwkeurig bekeken en toegelicht, hetgeen ik erg heb gewaardeerd. 
Beste Pieter en Joyce, gedurende de jaren van de vervolgopleiding hebben we met veel inzet 
het grote cohort achalasie patiënten behandeld, vervolgd, opgespoord en vooral vertroeteld. 
Het was een enorme inspanning naast de opleiding. Met deze gegevens was het mogelijk 
verder onderzoek te verrichten. Pieter je hebt de patiënten in een database gezet en een 
opzet gemaakt voor 2 artikelen. Joyce, hoofdstuk 7 komt van jouw hand. Veel dank hiervoor.
Beste Caspar, Ewout en Bettina, statistiek is niet mijn ding. Ik ben heel blij met jullie hulp en 
kennis op dit gebied wat heeft geleid tot mooie publicaties. Veel dank voor jullie geduld en 
uitleg.
Beste Wendy en Bernadette, heel veel dank voor jullie hulp en sturing bij allerlei logistieke 
noodzakelijke zaken.
Dr. P.J. Stijnen, opleider, beste Pieter, met heel veel plezier denk ik terug aan de jaren in Breda. 
Hoewel de lat steeds hoog lag (we moesten natuurlijk wel als beste scoren op de BOIG-
examens) heb ik de sfeer in “de Baronie” altijd uitstekend gevonden. Ik heb er ontzettend 
veel geleerd en vaak hoor ik jouw one-liners nog in mijn hoofd naklinken. Dankzij jou kon 
ik starten met de opleiding interne geneeskunde, dat ik later overstapte naar de MDL heb je 
altijd toegejuicht. Heel veel dank en ik hoop dat we elkaar nog vaak spreken.
Dr. H.S.L.M. Tjen, opleider, beste John, na de periode in Breda kwam ik voor de vervolgoplei-
ding naar het SFG. Daar werd de interesse voor de MDL verder gewekt door de wekelijkse 
sessies op de endoscopie-kamer. De polikliniek stage was met name erg gezellig, op vrijdag 
werden naast alle patiënten ook nog even de plannen voor het weekend doorgenomen, 
waar je dan maandag nog even op terug kwam. Je was een sociaal bewogen opleider met 
interesse in de mens achter de arts-assistent. Ook jou hoop ik in de toekomst nog vaak te 
spreken. 
Beste Antonie, Luuk, Marie-Paule en Rachel, het is er dan eindelijk van gekomen. Jullie heb-
ben (net als ik) altijd geloofd dat het af zou komen. Ik werk met zeer veel plezier met jullie 
samen. Vanaf nu kan ik mij nog meer inzetten voor het belang van de vakgroep, maatschap 
en het ziekenhuis. Ik hoop dit nog veel jaren met jullie samen te kunnen doen.
Beste maten, veelvuldig kreeg ik de vraag of het boekje er nou echt wel zou komen en 
zie…… Bedankt voor het vertrouwen en de ruimte, die ik de afgelopen 6 jaar heb gekregen 
om mij met het afronden van deze promotie bezig te houden. We gaan met de maatschap 
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een spannende tijd tegemoet waarin belangrijke beslissingen moeten worden genomen. Ik 
heb hierin het volste vertrouwen en hoop me nog heel lang thuis te voelen in de maatschap.
Lieve Abha, opleidingsmaatje en lieve vriendin. Samen op congres is steeds supergezellig. We 
gaan nu steeds zelf op zoek naar een leuk (natuurlijk wel een beetje luxe en shoptechnisch 
handig gelegen) hotel en dat is steeds heel goed gelukt (net als het shoppen natuurlijk). Ik 
hoop dit nog vele jaren met je te doen, naast natuurlijk de gezellige afspraakjes met onze 
gezinnen.  
Lieve Annie, Lies en Sharon, al 22 jaar een hecht meidengroepje. De meidenavonden met 
het beroemde rondje kwalen zijn me heel dierbaar. Het is heerlijk om je hart te luchten en 
te zien hoe iedereen met dezelfde problemen worstelt. Lies en Sharon jullie helpen vandaag 
om de grote dag in goede banen te leiden en Anneke (Annie) jij bent mijn paranimf. Je hebt 
waarschijnlijk nog slechter geslapen dan ikzelf. Dank voor jullie trouwe vriendschap.
Lieve Debbie, al vanaf het eerste studie jaar zijn we bevriend. Vroeger met z’n 4-en eindeloos 
spelletjes spelen en vooral heel veel lachen, nu met onze gezinnen weekendjes en dagjes op 
stap. Ik was jouw getuige, jij bent vandaag mijn paranimf. Ook al spreek en zie ik je door ons 
drukke leven en door de afstand minder vaak dan ik zou willen, ik weet dat het goed zit en 
dat je ervoor me bent! 
Lieve Carla en Marius, steeds een luisterend oor en vooral heel veel hulp bij de opvang van 
de kinderen. Jullie zijn ontzettend flexibel en altijd bereid tot extra hulp op welke manier dan 
ook. Ik hoop dat jullie nog lang in goede gezondheid in ons leven zijn.
Lieve Pa en Ma, het “werkstuk” is af. Dankzij jullie opvoeding die me voldoende discipline 
heeft opgeleverd en de boodschap dat het een voorrecht is om te mogen studeren. Zonder 
jullie oppas/babysit hulp gedurende al die jaren was het niet gelukt. Pa, het is een klein 
wonder dat je er bent vandaag en daar ben ik heel erg dankbaar voor. Jullie zullen vast wel 
apetrots zijn.
Lieve Kasper en Lieve Tessa, ik geniet iedere dag weer van jullie. Jullie maken dat al het andere 
relatief geworden is. Jullie aanwezigheid, liefde, spel, en zelfs geruzie zijn me heel dierbaar. 
Allerliefste Jochem, al vanaf het eerste practicum tijdens het eerste studiejaar delen we al 
het lief en leed. Promoveren, opleiding, werken met alle verplichtingen die daarbij horen en 
2 kinderen krijgen. De laatste jaren vrijwel iedere avond met de laptop op schoot ploeteren 
aan onze administratie en artikelen. Natuurlijk had er één dan wel eens een flinke dip maar 
gelukkig was daar de ander die met een peptalk alles weer op de rit kon zetten. De gedachte 
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dat we nu meer tijd samen zullen hebben is een utopie maar ik zal proberen het evenwicht 
meer in het midden te krijgen. En zullen we na jouw boekje dan eindelijk ons huis maar eens 
afklussen??  
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